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Mast cells are known for their role in allergic reactions via the IgE-antigen complex 
and degranulation. Mast cells are resident in most healthy tissues, including the prostate. In 
addition, mast cells are present in higher densities in prostate cancer with lower Gleason 
scores than in higher Gleason scores, suggesting potential interactions between mast cells 
and cancer cells. Consequently, a number of studies have explored the relationship between 
mast cell density and prostate cancer progression, albeit with varied results. Contradictions in 
the literature on whether mast cell density is associated with a good or poor prognosis may be 
due to variability in sampling or staining methods, or may represent true phenotypic 
differences between mast cells inside and outside the tumor.  
In this dissertation, we sought to explore the relationship between mast cells and prostate 
cancer progression and race disparities, as well as explore phenotypic differences between 
mast cells located inside or outside the tumor. The association between mast cells and 
prostate cancer progression was accomplished via a double immunohistochemistry (IHC) 
stain for mast cell tryptase and epithelial Cytokeratin-8 (Ck8) on a tissue microarray (TMA) 
set designed to determine associations with biochemical recurrence (PSA progression) after 
prostatectomy. Total mast cell number, mast cell density (mast cell number/tissue area), and 
mast cell number per epithelial or stromal area was assessed via a novel Aperio-based image 
analysis software termed PIP. Our findings indicate that high intratumoral mast cell density is 
associated with a lack of PSA recurrence, while high extratumoral mast cell density was 
correlated with a higher likelihood of PSA progression. Analysis of a role for mast cells in 
prostate cancer racial disparities was accomplished via similar staining of several matched 
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African American (AA) and Caucasian American (CA) prostate cancer TMAs. Results 
indicated that tumors from AA men with lower grade tumors (Gleason grade ≤ 3+4=7) had 
significantly lower numbers of mast cells than CA men matched on age, grade, and stage. 
Furthermore, intratumoral mast cell numbers in tumors from AA men had a similar 
relationship with PSA progression as in the PSA progression TMA study, and we 
additionally observed an association between lower intratumoral mast cells and increased 
rates of metastasis in both CA and AA men.  
Finally, using a number of techniques, the mast cell phenotype inside and outside the tumor 
was explored. Mast cell subtype was determined in AA and CA prostate tissues using double 
immunofluorescence (IF) staining for mast cell tryptase and chymase. Mast cells located in 
the tumor and benign regions and their immediate microenvironment were captured by laser 
capture microdissection (LCM) followed by RNA sequencing (RNAseq). These experiments 
revealed numerous differentially expressed genes between intratumoral and extratumoral 
mast cells. To validate and further expand on these findings, C-kit variant 1, CXCR4, and 
TFE3, were evaluated using quantitative PCR and in situ hybridization techniques.  
In addition, we employed two animal models to elucidate the role of mast cells in tumor 
invasion in the rodent prostate. In a rat model whereby pre-invasive neoplastic lesions are 
induced by the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), 
mast cell numbers were quantified in the ventral prostatic lobes of rats that had been treated 
with PhIP and then aged another 32 weeks. This allowed us to elucidate that mast cell 
number was increased long after exposure to PhIP, specifically in the ventral prostate. We 
also crossed a mast cell knock-out mouse, known as the Wsh mouse, with a well-known 
prostate cancer mouse model induced by overexpression of the oncogene cMYC (HiMyc), in 
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order to determine if the absence of extratumoral mast cells would result in lower invasive 
tumor area in the mouse prostates. These results confirmed our hypothesis by demonstrating 
that mast cell knock-out mice displayed a lower overall invasive cancer area. In addition, we 
found that the dorsal-lateral lobe of the prostate both contained the highest number of mast 
cells of all the lobes, as well as the highest invasive tumor area. The results from both rodent 
models suggest a role for mast cells in the lobe specificity of these rodent models, as well as 
a potential role for mast cells in early tumor development and invasion. 
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I. INTRODUCTION: MAST CELLS IN PROSTATE CANCER 
Mast cells are best known for their role in allergic reactions, where IgE-antigen 
complex (IgE-Ag) binding to the mast cell receptor FceRI stimulates degranulation, releasing 
effector molecules such as histamine, serotonin, leukotrienes, and proteoglycans 1,2. 
However, mast cells have also been shown to play significant roles in defending against 
parasites, controlling bacterial infection, and producing immunoregulatory cytokines 1,3-6. 
What makes mast cells particularly interesting in cancer biology, however, lies in the 
dynamic way in which these cells reside in and interact with the microenvironment in their 
target tissues. Mast cell functions can have potent effects on their environment that can be 




Figure 1.1 Potential biological roles for mast cells in prostate cancer. Photomicrograph 
shows a region of human prostatic adenocarcinoma stained for mast cells (brown staining 
cells) by immunohistochemistry. Original magnification, x 100 
 
These functions are dynamic and subject to manipulation by outside forces, possibly 
even by the surrounding cancer cells 1,7. As such, it is likely that mast cells play distinctive 
roles in different cancers types and across stages 8. This possibility is, in fact, reflected in the 
literature. There have been a number of studies in numerous cancers attempting to correlate 
mast cell density in or around the tumor, with the results varying from associating mast cell 
density with good prognosis, poor prognosis, or having no association with prognosis at all, 
even between studies in the same tumor type 1,8-24 . In prostate cancer specifically, higher 
numbers of “intratumoral” mast cells have been shown to be correlated with lower Gleason 
grade and better prognosis 22-24, however the opposite finding has also been reported 25. 
These and other studies on mast cells in human cancers were performed using a variety of 
techniques and without a standardized definition of “intratumoral” versus “peritumoral” mast 
cells. Nevertheless, the notion of mast cells having different effects in different 
circumstances is an attractive one, and is consistent with what is known about mast cell 
biology.   
Mast cells, like most immune cells, originate in the bone marrow. However, mast 
cells travel to their targets before their final stages of development, and their final 
differentiation into different subtypes is dictated in large part by the microenvironment of 
their resident tissues 1,7. The two main subtypes of mast cells are commonly known as MCTC, 
which express chymase, tryptase, carboxypeptidase, and cathepsin G and are usually found in 
mucosa, and MCT, which express mainly tryptase, and are usually localized to connective 
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tissues 3,26,27.  These two subtypes also differ in number, type, and content of secretory 
granules, as well as which stimuli to which they will respond 7. These subtypes are not 
exhaustive, however, as mast cells have been discovered with additional phenotypes 7. In 
addition, there is evidence to suggest that mast cell differentiation is not final, and the 
phenotype and mast cell protease profile can be changed based on different conditions in 
their microenvironment, including exposure to different cytokines, the presence of 
fibroblasts, and different host organ tissues 1,28,29. As such, it is reasonable to suggest that 
mast cell phenotype will differ depending on the conditions, such as in vitro versus in vivo, 
and in different cancers and cancer stages.  
The best known method of mast cell effector function is via degranulation, which is 
the release of the previously synthesized contents of intracellular granules in response to IgE-
Ag binding to the mast cell receptor. These contents include effector molecules such as 
serotonin, histamine, heparin, tryptase, and chymase, among others, many of which with pro-
inflammatory, anti-tumorigenic properties (Figure 1.1). However, there is also evidence for a 
method for “piecemeal degranulation” of mast cells, allowing for the selective release of 
cytokines without the release of the entire secretory granule 30. This alternative activation 
model helps to fuel the mechanistic side of the argument for the pro-tumorigenic potential of 
mast cells, as it provides the potential for the selective release of pro-tumorigenic cytokines 
such as IL-1 and IL-6 31 and effector molecules such as MMP9 in the absence of anti-
tumorigenic mast cell granule components. The mast cell subtype also comes into play here, 
as different subtypes will have distinctive effector molecules available to them, and thus can 
have different effects on the tumor upon degranulation, piecemeal or otherwise. In addition, 
mast cells are also potent producers of immune modulating cytokines, chemokines, 
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angiogenic factors, and proteases, all of which can cause significant changes in the tumor 
microenvironment 27.  
Mast cells are known to produce many different angiogenic molecules, including 
VEGF, histamine, TNFa, and Ang-1, and thus have been suspected for some time to play a 
significant role in tumor angiogenesis, and possibly even in the angiogenic switch 32. There 
have been several studies supporting this idea, including a transplantation multiple myeloma 
mouse model, in which it was found that transplanting mast cells with plasmacytoma tumors 
resulted in significantly higher vascularization 33. In addition, one study in a squamous 
carcinoma mouse model demonstrated a significant decrease in pre-malignant angiogenesis 
in mast cell deficient mice 34. Evidence in humans for a role for mast cells in tumor 
angiogenesis is also mounting, such as in one study correlating melanoma progression with 
mast cell density and simultaneously increased vascular density 15. However, some have also 
suggested a role for mast cells in suppressing angiogenesis by providing receptors that can 
“soak up” angiogenic factors 7.  In addition, there are studies correlating mast cell density 
and cancer progression without finding a correlation with angiogenesis, suggesting that mast 
cells may also have a role in tumor promotion aside from blood vessel development 13,14. In 
human prostate cancer, mast cell densities have not been correlated to neovascularization, 
however in an orthotopic rat model, implantation of AT-1 tumor cells resulted in peritumoral 
recruitment of mast cells and an increase in peritumoral vascular density 22. Furthermore, 
castration was found to result in mast cell recruitment to the prostate both in men and in the 
AT-1 tumor model and the Dunning rat model, and this correlated to an increase in vascular 
density in the Dunning model 22. 
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In addition to the possible roles for mast cells in angiogenesis, the role of mast cells 
in tissue remodeling is of particular interest in tumor promotion and includes a possible 
connection in prostate cancer. The idea that the extracellular matrix (ECM) plays a 
significant role in tumor promotion has gained importance in recent years 35-37. Mast cells 
produce potent proteases, including chymase, tryptase, collagenases, MMP9 and other 
gelatinases, and cysteinyl cathepsins. As such, research into the role of mast cells in ECM 
modulation and tumor invasion is also gaining ground 27. One study in prostate cancer 
explored the role of mast cell MMP9 in early prostate tumor progression in transgenic 
adenocarcinoma of the mouse prostate (TRAMP) mice, arguing that lower grade prostate 
tumors would need mast cell-derived MMP9 for invasion, since well differentiated prostate 
tumor cells do not produce MMP9 38. The results did in fact suggest that mast cell MMP9 
was necessary for early tumor invasion in mice. Immunohistochemistry (IHC) studies in 
human prostate cancer tissues showed a positive correlation between increased mast cell 
density, MMP9 production confined almost entirely to tumor-infiltrating mast cells, and well 
differentiated tumors – supporting the observations observed in the TRAMP mouse studies 
38.  Whether mast cell-derived MMP9 plays a role in driving early invasion of human prostate 
cancer is yet to be elucidated.   
In addition to the direct effects mast cells might have on cancer cells and their 
microenvironment, mast cells may also affect cancer through their roles as potent immune 
modulators. Mast cells are capable of both suppressing and promoting inflammatory 
responses, depending on the circumstances 1. In fact, mast cells are known to produce a 
number of cytokines and chemokines capable of recruiting, activating, suppressing, and 
driving the differentiation of both innate and adaptive immune cells, including neutrophils, 
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basophils, macrophages, lymphocytes (such as B cells, TH2 T cells, and Treg cells), and 
natural killer cells. As such, mast cells are also capable of anti- or pro-tumorigenic effects 
through the suppression or activation of the inflammatory response, and could also have a 
significant effect on other inflammatory cells in different cancers. 
Studies both in vivo in mice and in vitro using mouse and human cells have 
demonstrated that mast cells directly influence cancer cells, with one in vivo study showing 
decreased mitotic index and increased apoptosis in intestinal polyps, and two in vitro studies 
showing increased proliferation and invasion upon treatment with mast cell conditioned 
medium 27,39-41. This activity of mast cells has been theorized to be due to the production of 
tryptase, which is reported to promote proliferation of colon cancer cells, fibroblasts, and 
other cell types 42-47. Mast cell histamine has also been suggested to play a role in tumor cell 
proliferation, however the literature is not in agreement on whether it promotes or suppresses 
proliferation 7. In contrast, mast cell effector molecules such as IL-4 and TNFα could result 
in tumor cell death 5,48. 
As mast cells and cancer cells evolve in the same microenvironment, the interactions 
between these cell types could change significantly. With the myriad of mast cell effector 
molecules, there is a delicate balance between the anti- and pro-tumorigenic capabilities of 
mast cells that can conceivably change dramatically with time, even within the same tumor. 
It is also possible that even if mast cells cannot serve as an independent prognostic factor for 
all cancers, they might be an indicator of cancer aggressiveness and invasiveness 1. In 
addition, it is important that this ever-evolving relationship with cancer be better understood 
before any mast cell-targeted therapies are attempted. Since mast cells may have the potential 
to be pro-tumorigenic or anti-tumorigenic depending on the microenvironment, even in the 
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same cancer, certain therapies may be beneficial at certain stages of cancer, and detrimental 
in others 8,38. As such, mast cells have great potential in cancer research, and the many 
possible roles of mast cells in prostate cancer continue to be an important area of study.  
 
II. LOW INTRATUMORAL MAST CELLS ARE ASSOCIATED WITH 




Mast cells are of interest in prostate cancer because they possess both pro- and anti-
tumorigenic properties and are present in the tumor microenvironment. We studied the 
association of mast cell count and densities with prostate cancer recurrence using tissue 
microarrays (TMAs) for 462 men who recurred (cases) and 462 controls that were matched 
to the cases nested in a cohort of radical prostatectomy patients. Dual-immunostaining for 
mast cell tryptase and epithelial cytokeratin-8 and whole slide image analysis were used to 
assess total mast cell number, mast cell density (mast cell number/tissue area), and mast cell 
number per epithelial or stromal area in TMA spots containing tumor (up to 4 per man). We 
used conditional logistic regression to estimate the odds ratio (OR) and 95% confidence 
interval of recurrence for the mean, minimum, and maximum mast cell parameters in tumor 
tissue among each man’s TMA spots. After taking into account matching factors of age, race, 
Gleason sum, and pathologic stage, higher minimum mast cell density in the tumor 
(comparing highest to lowest quartiles: OR=0.58, 95% CI 0.40-0.86; P-trend=0.004) was 
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associated with a lower risk of recurrence. Patterns for mast cell number and ratio of mast 
cell number to epithelial or stromal area were similar to those for mast cell density. Our 
results suggest that intratumoral mast cells may be protective against prostate cancer 




Inflammation is known to play a significant role in the development of many cancers, 
and may promote carcinogenesis and cancer progression through a variety of mechanisms 
including stimulating tissue remodeling and tumor-promoting changes in the extracellular 
matrix, loss of tissue architecture, DNA damage due to oxidative stress, promotion of 
angiogenesis, and direct stimulation of tumor cells via cytokines 7,49,50. Evidence for a 
potential role for inflammation in prostate cancer is steadily building, as inflammation is 
frequently observed upon histological examination of prostate biopsies, radical prostatectomy 
specimens, and autopsy prostate specimens 51. Likewise, inflammation is proposed to be a 
key factor in the development of a risk-factor/putative precursor lesion called proliferative 
inflammatory atrophy (PIA) that is frequently seen to be in transition to prostatic 
intraepithelial neoplasia (PIN) and at times directly to adenocarcinoma 52-54. Multiple studies 
have also found significant correlations between genetic polymorphisms and aberrant 
expression of inflammation-related genes in prostate cancer 51,53,55. In addition, inflammatory 
cells and mechanisms of immune modulation and tolerance have been suggested to play key 
roles in castration resistance 56-58. However, the inflammatory cell profile in different regions 
or stages of prostate cancer, and the mechanisms by which this inflammation may be 
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contributing to progression and recurrence are not well understood 51. There is evidence 
suggesting roles for both adaptive and innate immune cells, with T and B cells emerging as 
having roles in castration resistance and immune tolerance, and macrophages possibly having 
a driving role in prostate cancer progression and metastasis 56-61. In addition to these cell 
types, mast cells are emerging as immune cells of particular interest in prostate cancer 
etiology 62. 
 
Mast cells are of interest in the context of cancer for a variety of reasons. Mast cells 
are resident in many tissues throughout the body, including the prostate, and, unlike many 
inflammatory cells, do not undergo full differentiation until they are established in the tissue 
microenvironment 7,28. This differentiation may not be final, however, and there is a 
possibility that mast cells within a tumor will be markedly different in their protease profile 
or subtype than mast cells outside the tumor 1,28,63,64. In addition, mast cells may have the 
ability to change their profile as the tumor microenvironment evolves 1,28,63,64. This potential 
for plasticity is relevant since mast cells are extremely diverse in their functions, and have 
both pro- and anti-tumorigenic properties and functions 8,63. For instance, mast cells are 
highly pro-inflammatory upon degranulation, and are known to recruit neutrophils, 
eosinophils, macrophages, and B and T cells capable of mounting an anti-tumor immune 
response 8,65-67. In contrast, mast cells are also potent producers of VEGF that could promote 
angiogenesis, and MMP9 that could modulate the extracellular matrix and possibly promote 
tumor invasion 7,8,65,68. Mast cells have been shown to interact with T and B cells, regulatory 
T cells, neutrophils, natural killer (NK) cells, dendritic cells, and macrophages, and produce 
cytokines that can both modulate the immune system (e.g. IL-17) and directly stimulate 
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tumor cell proliferation (e.g. histamine) 7,66,69,70. Since mast cells have so many pro- and anti-
tumorigenic properties, as well as the ability to change their profiles according to their 
microenvironment, there are a diverse number of roles that mast cells could potentially play 
in cancer 7,63,71,72. Indeed, in prostate cancer, there are conflicting reports as to whether mast 
cells play a pro- or anti-tumorigenic role in the disease, or if mast cell numbers serve as a 
positive or negative prognostic factor 8,63.  
 
It has been consistently reported that mast cell numbers are increased in areas of 
prostate cancer versus benign prostate tissues, and that mast cells are higher in density in 
lower Gleason grades than in higher Gleason grades 23,24,69,73,74. However, the literature 
reporting the prognostic value of mast cells in prostate cancer is far less consistent 8,63, with 
some studies reporting that high intratumoral mast cell numbers are associated with favorable 
prognosis 24,74 and some reporting that low intratumoral mast cell numbers are associated 
with favorable prognosis 75. Commonly used markers for mast cells include the cell surface 
receptor c-kit 76 and the most abundant mast cell granule component tryptase 77. Fleischmann 
et al. stained a 2,300 patient TMA with immunohistochemistry (IHC) for c-kit and reported 
that higher mast cell densities were significantly associated with longer prostate specific 
antigen (PSA) recurrence-free survival 24. Likewise, Johannson et al. used IHC for tryptase to 
identify mast cells in a TMA set of transurethral resection tissues from 394 patients with 
prostate cancer and also reported that high mast cell density in tumor tissue was associated 
with longer cancer-specific survival 74. Interestingly, this group found that in surrounding 
“peritumoral” benign stroma, higher mast cell densities correlated with shorter cancer-
specific survival 74. Whereas peritumoral mast cell numbers (e.g. mast cells directly adjacent 
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to tumor) have been examined in multiple studies 64,73,74,78, the association between mast cell 
numbers in benign regions distant to the tumor and outcomes has not been examined.  
 
In contrast to studies reporting an inverse association, Nonomura et al. reported that 
in 104 patient biopsies stained for mast cell tryptase, higher intratumoral mast cell densities 
were significantly associated with worse PSA-free survival 75. The differences in findings 
among studies may be due to differences in study methods such as choice of mast cell marker 
(e.g., detection of c-kit versus tryptase) and tissue sample type (biopsies versus TMAs). The 
differences may also relate to variations in mast cell numbers in different regions of the 
tumor and associated sampling issues, including accounting for benign glands that can be 
admixed with tumor glands. 
 
Taken together, the association between mast cell numbers or density within the 
tumor and prostate cancer recurrence remains uncertain. Furthermore, we aimed to examine 
the association between mast cell numbers or density in benign regions of the prostate distant 
to the tumor and recurrence. In addition, while most reports have approached the study of 
mast cells from the perspective of mast cell density in a certain tissue area, we sought to 
determine whether any observed changes in mast cell numbers were related to either 
epithelial or stromal area. Thus, in the present study, we evaluated the association between 
mast cell numbers in both benign and cancerous regions of the prostate and prostate cancer 
recurrence in men treated by prostatectomy in the “PSA” era (i.e. after PSA testing became 
widely used and available). We conducted this work among 462 men who recurred (cases) 
and 462 controls matched to the cases on prognostic factors nested in a cohort of radical 
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prostatectomy patients at the Johns Hopkins Hospital. We measured the ratio of mast cell 
number to total tissue area (mast cell density), total epithelial area, or total stromal area in 




Study population, design, and tissue. The design of the nested case-control study of 
prostate cancer recurrence has been described previously 79. The sample set included men 
who underwent radical prostatectomy for clinically localized prostate cancer at The Johns 
Hopkins Hospital between 1993 and 2001, and had not received hormonal or radiation 
therapy before radical prostatectomy or adjuvant therapy before recurrence. Cases (n=524) 
were men who experienced biochemical recurrence as measured by a re-elevation of serum 
prostate-specific antigen (PSA) ≥0.2 ng/mL, metastasis, or prostate cancer death after surgery 
by 2004. For each case, a control (n=524) was selected who had not experienced recurrence 
by the date of the cases’ recurrence and who was matched on age, race, pathological stage 
(T2, T3a, T3b or worse), and Gleason sum (<6, 6, 7, 8+). For these recurrence cases and 
controls, we previously constructed TMAs containing matched tumor (4 cores, 0.6 mm) and 
benign tissues (2-4 cores, 0.6 mm). The benign tissue areas used for the TMA construction 
were generally taken from regions lacking overt inflammatory cell infiltrates when possible. 





Assessment of mast cells. Mast cells were identified by positive IHC staining for tryptase 
coupled with image analysis. 
 
IHC. We developed an IHC double stain for mast cell tryptase in red and epithelial cell 
cytokeratin-8 (ck-8) in brown. Slides containing the TMA sections were deparaffinized in 
xylene and rehydrated through a series of graded ethanol, followed by water and 1% tween in 
water. The slides were then steamed for 45 minutes in HTTR for antigen retrieval and treated 
with a dual peroxidase block for 5 minutes. Slides were then incubated at room temperature 
with 1:40,000 dilution of Abcam mouse anti-tryptase antibody (AA1) and 1:800 dilution of 
rabbit anti-cytokeratin 8 (ck-8, EP1628Y) for 45 minutes, followed by a cocktail of AP 
conjugated anti-mouse secondary and HRP-conjugated-anti-rabbit secondary antibody at 
room temperature for 30 minutes. The slides were then treated with DAB (ck-8 positive cells, 
brown) and Vector Red (tryptase positive cells, red) for 20 minutes each for visualization. 
The quality of the IHC was assessed by visualization (e.g., confirming brown staining of 
epithelium and red staining of stromal mast cells) prior to scanning (20x objective; 0.49 μm 
per pixel) with an Aperio ScanScope® CS linear-array scanner (Leica Biosystems). After the 
TMA slides were scanned, the TMA whole slide images were segmented into individual core 
(JPEG) images using TMALab in eSlideManager (Leica Biosystems). A pathologist 
examined each core image and an adjacent H&E TMA core image to verify the tissue 
diagnosis (tumor versus benign) and to document any missing TMA spots that were absent 




TMA image analysis. We previously developed PIP (PIP is for Image Processing or PIP, 
v1.0-rc2, http://www.bitbucket.org/ncuka/pip), software for automated, parallelized image 
analysis of whole slide images and TMAs 80. PIP is Java software that uses ImageJ version 
1.48e as its processing library 81. Using the PIP framework, we implemented a custom image 
analysis algorithm that identified tissue areas, DAB-positive (epithelial) areas and Vector 
Red-positive cells. Briefly, this algorithm used Hue-Saturation-Balanced (HSB) 
segmentation to measure DAB-positive areas and a combination of HSB segmentation and 
color deconvolution for identifying Vector Red-positive mast cells. Core images were 
concurrently processed in PIP running under Java 8 (version 1.8.0_11). Annotations of each 
identified region (tissue, DAB) and all mast cells were created for subsequent visual 
inspection. Algorithm parameters were tuned for use in this high-throughput method for the 
counting of mast cells within the prostate microenvironment (Figure 2.1A-F). The output of 
PIP was used to measure the mast cell count, mast cell count per total tissue area (mast cell 
density), mast cell count per total epithelial area defined as ck-8 positive area (MC/Ep), and 
mast cell count per stromal area (MC/Stroma) defined as total tissue area minus epithelial 
area. The image analysis algorithm excluded glandular lumens from tissue and DAB area 
measurement (see Figure 2.1C). To validate this method, we randomly chose 30 TMA spots 
(15 benign, 15 tumor) to determine the correlation between the PIP automated count against 
a “gold standard” manual mast cell count. The automated count and the manual mast cell 
count for each TMA spot were highly correlated (Pearson correlation coefficient R2= 0.92, 
Figure 2.1G). Thus, the PIP software was found to be a valid alternative to manual counting, 




Whole slide image analysis. A series of whole tissue sections from 54 men with a range of 
Gleason sum tumors (6; n=10, 7; n=21, 8; n= 10, 9; n=13) were stained for mast cell tryptase 
and CK8 and scanned as described above. Each slide was then annotated using Aperio 
software to circle regions containing tumor. A script was generated to create a 200 micron 
“mantle” around each tumor to represent the peritumoral region (figure 2.4). The tumor and 
peritumoral regions were then analyzed for mast cell parameters with the PIP software as 
described above.  
 
Statistical Analysis. After excluding any missing TMA spots, 478 recurrence cases and 469 
controls remained for the tumor tissue spot analysis, and 476 recurrence cases and 474 
controls remained for the benign tissue spot analysis. For the primary analysis, we included 
only complete matched pairs of recurrence cases and controls for tumor tissue spots (462 
pairs, 924 spots total) and for benign tissue spots (465 pairs, 930 spots total). We compared 
means and prevalence of clinical and pathologic characteristics between recurrence cases and 
controls using the paired t-test and McNemar’s test, respectively. Then, for each man, we 
calculated the mean, minimum, maximum, and standard deviation of mast cell count, mast 
cell count/total tissue area, mast cell count/total epithelial tissue area, and mast cell 
count/total stromal tissue area among his up to 4 tumor-containing and among his up to 4 
benign tissue TMA spots. We compared these mast cell parameters between the cases and 
their matched controls using the Wilcoxon-sign-rank test. We divided these mast cell 
parameters into quartiles based on the distribution in the controls, and then used conditional 
logistic regression to estimate the odds ratio (OR) of recurrence associated with quartiles of 
the mast cells parameters taking into account the matching factors. In a sensitivity analysis, 
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we further adjusted for any differences between the cases and controls in the primary 
Gleason pattern. The formalin-fixed, paraffin-embedded (FFPE) tissue block age (based on 
calendar year of surgery) was not associated with mast cell count/total tissue area in cases or 
controls (data not shown), therefore we did not adjust for block age. In controls, mast cell 
parameters in cancer and benign tissue were not associated with pre-surgery PSA with the 
exception of a possible weak association for mast cell count/stromal area (data not shown), 
therefore we did not adjust for pre-surgery PSA. 
 
In controls, we compared the mast cell parameters between higher-grade (Gleason sum of 
4+3 or higher) and lower-grade (Gleason sum 3+4 and lower) disease using the Wilcoxon-
rank sum test. Again in controls, we used logistic regression to estimate the OR of higher-
grade (versus lower-grade) disease associated with quartiles of the mast cell parameters 
adjusting for age, race, and pathologic stage. In the series of whole tissue sections, we 
compared mast cell density between higher-grade and lower-grade disease using the 
Wilcoxon-rank sum test. 
 
All tests were 2-sided and a p-value <0.05 was considered to be statistically significant. 










Recurrence cases and matched controls included in the analysis were similar on the 
demographic (about 59 years old, majority white), clinical, and pathologic characteristics that 
were matching factors. 
 
Mast cell density in tumor tissue is lower and in benign tissue is higher in recurrence 
cases than in controls. For all mast cell parameters assessed, the minimum, rather than the 
mean, maximum or standard deviation, among a man’s TMA spots in tumor and benign 
tissue was the most robustly different between recurrence cases and controls (Tables 2.1-2.2). 
Thus, we present results for the minimum throughout. Specifically, the minimum mast cell 
density among a man’s TMA spots was lower in recurrence cases than in controls (Figure 
2.1A). In contrast, this minimum in benign tissue was higher in recurrence cases than in 
controls (Figure 2.2B). These patterns in tumor and in benign tissue were also observed for 
the minimum of the other mast cell parameters calculated – mast cell count, MC/Ep, 
MC/Stroma (Tables 2.1-2.2).  
 
In controls, minimum mast cell density did not statistically significantly differ between tumor 
and benign tissue from the same men, although the mean mast cell density was statistically 





Table 2.1. Mean mast cell distributions* in tumor tissue among prostate cancer recurrence 
cases and controls, Brady Recurrence Nested Case-Control Study. 
                                   Tumor Tissue 
 










Count         
   Minimum 462 19.12 15.26  462 17.38 15.03 0.003 
   Maximum 462 41.94 32.4  462 41.07 36.03 0.2 
   Mean 462 29.82 21.54  462 28.18 22.84 0.02 
   Standard    
   deviation 
440 11.1 11.67 
 
444 11.78 13.25 0.6 
Density         



























   Standard   













MC/Ep         





























   Standard  










MC/Stroma     
   
 






























   Standard       













*Most men had two or more TMA spots per tissue type. In the analysis, the minimum, 
maximum, mean, or standard deviation of each man’s TMAs spots was used in the statistical 
analysis. The sample size for the analysis using the standard deviation is smaller than for the 




Table 2.2. Mean mast cell distributions* in benign tissue among prostate cancer recurrence 
cases and controls, Brady Recurrence Nested Case-Control Study. 
 
Benign Tissue  











Count         
   Minimum 465 13.95 11.27  465 15.95 10.61 0.0001 
   Maximum 465 27.67 19.5  465 29.74 19.89 0.07 
   Mean 465 20.47 13.62  465 22.60 14.10 0.008 
   Standard  437 8.28 8.31  445 8.57 9.13  
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   deviation 0.9 
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*Most men had two or more TMA spots per tissue type. In the analysis, the minimum, 
maximum, mean, or standard deviation of each man’s TMAs spots was used in the statistical 
analysis. The sample size for the analysis using the standard deviation is smaller than for the 




Figure 2.1. PIP software for automated, high-throughput analysis of mast cells in 
prostate TMAs. TMAs were double immunostained for cytokeratin 8 in DAB (brown) and 
mast cell tryptase in AP-Vector Red. Stained TMAs were then scanned, segmented into cores 
and processed using a custom algorithm implemented in PIP. A, D. Examples of IHC double 
stain of benign and tumor (respectively) prostate tissue spots. B, E. Examples of PIP software 
processing of prostate tissue TMA spots. Areas without tissue are blacked out, brown ck-8 
areas are circled in blue, and red tryptase-positive mast cells are indicated by green markers. 
C, F. Higher power views of inserts from B and E, respectively. G. Comparison of manual 






Figure 2.2. Lower minimum mast cell density in tumor and higher minimum mast cell 
density in benign tissue are associated with prostate cancer recurrence. Graphical 
representation of mast cell densities in tumor and benign TMA spots from recurrence cases 
and controls. A) Minimum mast cell density in tumor tissue is statistically significantly lower 
in recurrence cases than controls (p = 0.0005). B) Minimum mast cell density in benign 
tissue is statistically significantly higher in recurrence cases (p = 0.02). 
 
Higher minimum mast cell density in tumor tissue is associated with lower risk of 
prostate cancer recurrence. Risk of prostate cancer recurrence decreased across quartiles of 
the minimum of each of the mast cell parameters in tumor (Table 2.3). The strongest inverse 
association with recurrence was for mast cell density (P-trend=0.004): comparing the highest 
quartile of mast cell density to the lowest, the OR of recurrence was 0.58 (95% CI 0.40-
0.86). Because cases and controls were matched by Gleason sum rather than Gleason pattern, 
in a sensitivity analysis we additionally adjusted for differences in the primary Gleason 




Table 2.3. Association between quartiles of minimum* mast cells parameters in tumor or 
benign tissue and risk of prostate cancer recurrence, Brady Recurrence Nested Case-Control 
Study. 
 


















OR 95% CI 
P-
value 
   1 (lowest) 154/126 1 Reference    96/121 1 Reference  
   2 134/118 0.87 
(0.61-
1.23) 




   3 77/109 0.53 
(0.36-
0.80) 




   4 (highest) 97/109 0.66 
(0.44-
0.98) 




  P-trend 0.02     <0.001 
Density          
   1 (lowest) 150/116 1 Reference    98/114 1 Reference  
   2 126/115 0.81 
(0.57-
1.16) 




   3 94/117 0.6 
(0.41-
0.87) 




   4 (highest) 92/114 0.58 
(0.40-
0.86) 




  P-trend 0.004     0.007 
MC/Ep   
        
   1 (lowest) 152/116 1 Reference    88/117 1 Reference  
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   2 104/114 0.67 
(0.46-
0.97) 




   3 110/117 0.68 
(0.47-
0.99) 




   4 (highest) 96/115 0.6 
(0.41-
0.88) 




  P-trend 0.03     0.004 
MC/Stroma          
   1 (lowest) 150/116 1 Reference   104/117 1 Reference  
   2 126/115 0.81 
(0.57-
1.16) 




   3 94/117 0.6 
(0.41-
0.87) 




   4 (highest) 92/114 0.58 
(0.40-
0.86) 




  P-trend 0.01         0.07 
 
*Minimum value for a given mast cell parameter among each man’s TMA spots. **Quartile 
cut points based on control group, matched on age, race, pathologic stage, and pathologic 
Gleason sum, P-trend calculated using median of quartiles.  
 
Higher minimum mast cell density in benign tissue is associated with a higher risk of 
prostate cancer recurrence. In contrast to tumor, risk of prostate cancer recurrence 
increased across quartiles of the minimum of each of the mast cell parameters in benign 
tissue (Table 2.3). The strongest positive association with recurrence was for mast cell count 
(P-trend<0.001): comparing the highest quartile of mast cell density to the lowest, the OR of 








Risk of recurrence is highest for the combination of lower minimum mast cell density in 
tumor tissue and higher minimum mast cell density in benign tissue compared with all 
other combinations. Given the opposite direction of the associations with recurrence for 
high mast cell parameters in tumor and benign tissue, we next evaluated the association of 
mast cell parameters in the combination of tumor and benign tissue with recurrence. Low 
density in tumor tissue and high density in benign tissue was associated with a higher risk of 
recurrence compared with all other combinations (OR=1.87, 95% CI 1.36-2.58). However, 
no statistical interaction between mast cell density in tumor and benign tissue was present 
(P=0.2). 
 
Mast cell parameters in tumor, but not in benign tissue, are inversely associated with 
Gleason sum in controls. Given prior studies, we also investigated whether the mast cell 
parameters differed by Gleason sum (data not shown) and are associated with higher-grade 
disease in the controls. The OR of higher-grade disease increased across quartiles of the 
minimum mast cell count (P-trend=0.02), mast cell density (P-trend=0.01, Figure 2.3A), mast 
cell count to epithelial area (P-trend=0.02), and mast cell count to stromal area (P-
trend=0.02) in tumor (Table 2.4). The OR of higher-grade disease did not change across 







Table 2.4. Association of quartiles of minimum* number of mast cells in tumor and in 
benign prostate tissue with Gleason sum, controls, Brady Recurrence Nested Case-Control 
Study. 
 




Tumor tissue   Benign tissue 










OR 95% CI   
   1 (lowest) 154/126 1 Reference    96/121 1 Reference  
   2 134/118 0.56 
(0.29-
1.05) 




   3 77/109 0.51 
(0.25-
1.01 




   4 (highest) 97/109 0.42 
(0.21-
0.86) 




  P-trend 0.02     0.1 
Density          
   1 (lowest) 150/116 1 Reference    98/114 1 Reference  
   2 126/115 0.31 
(0.15-
0.64) 




   3 94/117 0.39 
(0.20-
0.75) 




   4 (highest) 92/114 0.4 
(0.20-
0.78) 




  P-trend 0.01         0.2 
MC/Ep           
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   1 (lowest) 152/116 1 Reference    88/117 1 Reference  
   2 104/114 0.76 
(0.52-
1.11) 




   3 110/117 0.81 
(0.55-
1.20) 




   4 (highest) 96/115 0.64 
(0.43-
0.95) 




  P-trend 0.02     0.7 
MC/Stroma          
   1 (lowest) 150/116 1 Reference   104/117 1 Reference  
   2 126/115 0.33 
(0.16-
0.66) 




   3 94/117 0.57 
(0.30-
1.06) 




   4 (highest) 92/114 0.36 
(0.18-
0.74) 




  P-trend 0.02     0.5 
 
*Minimum value for a given mast cell parameter among each man’s TMA spots. **Quartile 
cut points based on the distribution in the controls. P-trend calculated using the median of 
quartiles in the controls. Model adjusted for age, race, and pathologic stage. ***Higher-grade 








Figure 2.3. Minimum mast cell density is higher in lower Gleason sum tumors. This 
analysis was done in the controls. Graphical representation of minimum mast cell density in 
high (≥4+3=7) vs low (≤3+4=7) Gleason sum tumors. A) Minimum mast cell density in 
tumor tissue is statistically significantly higher in lower Gleason sum tumors (p=0.004). B) 
Minimum mast cell density in benign tissue is not different between high and low Gleason 
sum tumors (p=0.6). 
 
In the analysis of mast cell density in tumor versus peritumoral regions in the 54 whole tissue 
sections (Figure 2.4), we also observed significantly lower mast cell density in higher grade 
tumors (Gleason >7, P=0.006), and this pattern was also observed for the peritumoral regions 
analyzed (P=0.007, Figure 2.4). Although not statistically significant (P=0.3), lower mast cell 
densities were observed in higher grade tumors when separated by Gleason 3+4 or lower 





Figure 2.4. Whole slide image analysis. A) Section stained for CK8/tryptase where tumor is 
circled in red using Aperio annotation software. Image analysis of B) isolated tumor area and 
C) peritumoral region. 
 
 
2.5 Discussion and conclusions 
In this study of surgically treated men with clinically localized prostate cancer, we 
found that higher numbers of mast cells in tumor was associated with a lower risk of prostate 
cancer recurrence taking into account stage and grade at diagnosis. The most robust findings 
were observed when using the minimum mast cell count among each man’s TMA spots 
assessed. Our results suggest that intratumoral mast cells may be protective against prostate 
cancer recurrence and could potentially serve as a prognostic biomarker after prostatectomy.  
The inverse association with recurrence was also observed when standardizing mast 
cell count for area of total, epithelial, and stromal tissue. We hypothesized that mast cells 
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may maintain a certain ratio to epithelial cells, and that therefore mast cell numbers may be 
higher in cancer due to the higher epithelial cell to stromal cell ratio in cancer. However, the 
association for mast cell density (mast cell count to total tissue area) was more strongly 
inverse than for mast cell count to epithelial area. Thus, mast cell density may be the most 
useful measure of mast cell abundance in the context of prostate cancer recurrence.  
There are a number explanations as to why higher densities of intratumoral mast cells 
could be inversely associated with recurrence. Mast cells express MHC II to present antigens 
as well as the costimulatory molecule CD28, and are known to recruit neutrophils, 
eosinophils, macrophages, and B and T cells capable of mounting an anti-tumor immune 
response 65-67. Mast cells are also capable of producing molecules such as IL-4 and TNF-α 
that can have a negative impact on tumor cell growth and survival directly 7,82. In addition, it 
is possible that prostate cancer cells that are more likely to lead to recurrence undergo a 
molecular switch that prevents the recruitment of mast cells in response to the cancer, 
resulting in mast cells being a proxy marker for poor prognosis. The biological role of 
intratumoral mast cells and their possible use as a prognostic factor is worth further 
investigation. 
We also found that a higher number of mast cells in benign tissue was associated with 
a higher risk of prostate cancer recurrence. There are several possible explanations as to why 
mast cells in benign regions of a prostate that contains cancer could be associated with a 
greater likelihood of recurrence. Mast cells are highly pro-angiogenic and may serve to 
promote a pro-tumorigenic microenvironment and also promote metastasis 66. Mast cells are 
also theorized to promote tumor invasion via production of MMP9 and other collagenases, as 
well as proteases and other effector molecules capable of changing the tissue architecture 
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8,65,66,68. Mast cells are also capable of synthesizing and secreting a number of factors that 
may promote tumor proliferation, including histamine, NGF, SCF, and IL-8 63. Mast cells are 
also believed to recruit regulatory T cells (Tregs) and promote tumor immune tolerance 
66,70,83. 
Finally, higher mast cell numbers in benign regions of the prostate could serve as a proxy for 
a higher degree of chronic inflammation. Men with a higher degree of chronic inflammation 
in the benign regions the prostate may in turn be more likely to recur. Indeed, chronic 
inflammation in benign prostate tissues has been found to be associated with higher grade 
prostate cancer 84. One limitation of our study is that the benign areas used for the TMA 
construction were taken from region lacking overt inflammatory cell infiltrates when 
possible. To determine the generalizability of our findings, future studies should examine 
mast cell numbers in benign regions in the prostate sampled randomly.  
 
This study also sought to confirm prior studies showing that mast cell density is 
inversely associated with Gleason sum in cancer tissues, and we additionally assessed the 
association between mast cell density in benign tissues and Gleason sum. Our findings in the 
controls were consistent with prior studies in that cancer tissue mast cell densities as well as 
mast cell count, mast cell count/epithelial area, and mast cell count/stromal area were 
significantly higher in men with lower Gleason sum (≤3+4) than in higher Gleason sum 
(≥4+3) cancers. A similar finding was observed in whole tissue sections from a range of 
Gleason sum tumors analyzed for both tumor and peritumoral regions, but only when higher-
grade tumors were defined as Gleason sum >7. This result supports that TMAs may provide 
similar mast cell parameters information as whole tissue sections. We suspect the 3+4 versus 
4+3 analysis was underpowered in this small cohort. 
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In contrast, mast cell count in benign tissue was not associated with Gleason sum. 
These inconsistent associations between tumor and benign tissue suggest that mast cell 
alterations in the context of Gleason sum are specific to the tumor microenvironment, and not 
inherent to the prostate as a whole. Whether increased or decreased mast cell density in 
tumor tissue is related to prostate cancer outcome is still somewhat controversial in that there 
are mixed results reported so far 24,74,75. Our finding that a lower mast cell count in tumor 
tissue is associated with worse outcome independent of standard clinical and pathological 
variables (e.g. pathologic Gleason score and pathologic stage at prostatectomy) is consistent 
with those reported by Fleischmann et al., 24 and Johannson et al. 74 and together suggest that 
there may be an anti-tumor biological role for mast cells in prostate cancer tissue. We do not 
know why the minimum mast cell parameter of each man’s TMA spots was the most 
robustly different measure between recurrence cases and controls. We do know that mast cell 
numbers within different regions of the tumor could vary depending on a number of factors 
including the presence of other inflammatory cells and/or immune stimuli and local cytokine 
production. Thus, if intratumoral mast cells indeed do protect against recurrence, we 
speculate that the region with the lowest number (rather than the average number, the 
maximum number, or the variability in number across regions of the tumor) may provide the 
most information about risk of recurrence.  
Key strengths of our study include the large, well-characterized patient cohort 
coupled with the use of newly developed automated image analysis for unbiased detection 
and quantification of mast cells, tissue area, epithelial area, and stromal area on thousands of 
TMA spots. To support the clinical utility of our findings, mast cells in tumor and benign 
33 
 
areas sampled without respect to overt inflammation should be further investigated in 
additional prostate cancer patient populations. 
In summary, using a novel image analysis tool we report that a low number of 
intratumoral mast cells is associated with of a higher risk of prostate cancer recurrence. 
Furthermore, we observed that a high number of mast cells in benign tissue appears to be 
associated with a higher risk of recurrence. These findings suggest further investigations both 
to better understand mast cell biology in prostate cancer and to determine clinical utility. 
 
III. MAST CELLS IN PROSTATE CANCER RACE DISPARITIES AND 
METASTASIS 
3.1 Abstract 
Prostate cancer presents with a significant racial disparity, with African American (AA) men 
being twice as likely to be diagnosed with prostate cancer, and twice as likely to die from 
their disease. AA men are also typically diagnosed with prostate cancer at an earlier age and 
their tumors tend to be more aggressive (e.g. higher Gleason grade and stage) at diagnosis. 
Finally, biopsies from AA men have a higher prevalence and degree of inflammation. Given 
our previous results that low intratumoral mast cell densities are associated with greater rates 
of PSA progression (Chapter II), we next explored whether prostate cancer in AA men 
contains lower densities of intratumoral mast cells compared to Caucasian American (CA) 
men, and whether intratumoral mast cell densities in AA men are similarly associated with an 
increased risk of biochemical recurrence. Our previous study contained primarily tumors 
from CA men. We used multiple cohorts using TMAs constructed with tumor and benign 
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prostate tissues from AA and CA men matched on cancer grade and cancer stage. Our results 
showed that intratumoral mast cell densities were significantly lower in tumors of AA men in 
comparison to CA men specifically in low Gleason score cancers (Gleason ≤ 3+4=7). The 
pattern observed for low numbers of intratumoral mast cells and biochemical recurrence in 
the PSA Progression TMA set was present in all strata in both CA and AA men in the present 
study. This association remained when development of metastasis was the clinical endpoint. 
Thus, these results indicated that the same relationship between low numbers of intratumoral 
mast cells and worse prostate cancer outcomes was present for AA men, and additionally 
identified a potentially important relationship between low numbers of intratumoral mast 




Prostate cancer afflicts AA men to a greater degree than CA men, with AA men 
having significantly higher serum PSA levels, higher likelihood of positive surgical margins, 
60% greater incidence of prostate cancer, and 2-3 times higher mortality rates 85-89. The 
cause(s) of this racial disparity are unclear, and many mechanisms have been suggested 
including societal factors such as access to healthcare, Social Economic Status (SES), and 
lack of medical intervention due to distrust of the medical community 85,90-92.  While all these 
factors may contribute to the overall problem, there is evidence to suggest that these factors 
do not fully explain the racial disparity 93.  Intriguingly, focused studies in AA cohorts have 
revealed markedly different frequencies of somatic alteration in several genes. For example, 
ERG rearrangements have been observed in approximately half of all prostate tumors 
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occurring in CA men94, but these rearrangements are only seen in 25-30% of tumors in AA 
men 95,96. These data suggest that there are also biological differences in tumors from AA 
men. As such, many studies have further explored a biological explanation for racial 
disparities in prostate cancer. For example, Powell et al evaluated autopsy specimens of 
African American (AA) and European American (EA) men who died of causes unrelated to 
prostate cancer, as well as radical prostatectomy specimens of men diagnosed with cancer 87.  
Their findings showed that AA men had similar rates of preclinical prostate cancer and 
similar preclinical characteristics as EA men 87. However, radical prostatectomy specimens 
show a significantly higher tumor volume and Gleason Score in AA than EA men 87. In 
addition, the authors found that AA men were significantly more likely to have advanced or 
metastatic disease than EA men, with a ratio of 4:1 87. These findings indicate that prostate 
cancer in AA men has a higher rate of growth and may be more aggressive than in CA men. 
Similarly, an additional study found AA men to have a 61% likelihood of significant prostate 
cancer as compared to only 27% in CA men, as well as a significantly higher likelihood of a 
Gleason score of 7 or higher and a tumor volume greater than 0.5cm3 89. These studies did 
not, however, implicate a particular mechanism or genetic susceptibility explaining this 
higher growth rate and metastatic potential. 
Evidence is mounting for a role for inflammation in prostate cancer, with 
inflammation being frequently observed upon histological examination of prostate biopsies, 
radical prostatectomy specimens, and autopsy prostate specimens 97. In addition, 
inflammation is proposed to drive the development of a putative precursor lesion termed 
proliferative inflammatory atrophy (PIA), which may have the potential to develop into 
prostatic intraepithelial neoplasia (PIN) and then to adenocarcinoma 98-100. Finally, 
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inflammatory cells and mechanisms of immune modulation and tolerance have been 
suggested to play key roles in castration resistance 101-103. As such, there is significant 
possibility that higher rates of inflammation would be associated with higher rates of prostate 
cancer, as well as greater potential for advanced or metastatic disease. Interestingly, studies 
seeking to elucidate a mechanism to explain the racial disparity of prostate cancer are 
increasingly highlighting a differential rate of inflammation in the prostates of AA compared 
to CA men.  
AA men have been shown to have an increased prevalence of inflammation in 
prostate biopsies free of prostate cancer compared to CA men 86. In addition, microarray 
studies have identified differential gene expression profiles in prostate tumors from AA men 
compared to CA men that demonstrate a pattern of high representation of genes associated 
with inflammatory pathways, including IL-10, PTPN22, components of HLA complex, TAP 
1 and 2, TCR, IL4, IL13, CXCR4, CCL5/CCR5, and MMP9 88,93,104,105. Of particular interest, 
many of the genes identified as being higher expressed in tumors of AA men, namely IL4, 
IL13, CXCR4, CCL5/CCR5, and MMP9, are associated with chemotaxis and function of 
mast cells 106-109. 
Mast cells are immune cells resident in most tissues of the body, including the 
prostate, and are known to secrete effector molecules such as IL4, IL13, histamine, VEGF, 
and MMP9 109,110. In addition, CXCR4 and CCR5 are known to mediate mast cell progenitor 
chemotaxis 109. As was discussed in Chapters I and II, mast cells potentially contribute to 
angiogenesis, invasion, immune modulation, and tumor cell proliferation, and are highly pro-
inflammatory 70,110-116. As reported in Chapter II, we analyzed mast cell density in relation to 
biochemical recurrence in a cohort of radical prostatectomy patients using TMAs that 
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sampled both tumor and matched benign tissue 120. Our findings indicated that higher 
intratumoral mast cell density was associated with a lower risk of recurrence, while higher 
benign tissue mast cell density was associated with a higher risk of recurrence120. 
Due to the evidence suggesting a differential presence of prostatic inflammation in 
AA and CA men, as well as our previous data suggesting a relationship between mast cells 
and recurrence in men with prostate cancer, we investigated the potential role for mast cells 
in the race disparity of prostate cancer. We used a similar approach as outlined in Chapter II, 
thereby analyzing the maximum, median, and minimum mast cell density counts for tissues 
from AA and CA men. We utilized three different cohorts and TMAs representing tumor and 
benign prostate tissues from both AA and CA men. For one cohort in which outcomes data 
was available, we assessed mast cell density and correlated with risk of recurrence and 
development of metastases. In addition, distant metastases from rapid autopsy tissues from 
three prostate cancer patients were stained for tryptase to evaluate intratumoral mast cell 




IHC Staining. Slides containing the TMA sections were deparaffinized in xylene and 
rehydrated through a series of graded ethanol, followed by water and 1% tween in water. The 
slides were then steamed for 45 minutes in HTTR for antigen retrieval and treated with a dual 
peroxidase block for 5 minutes. Slides were then incubated at room temperature with 
1:32,000 dilution of Abcam mouse anti-tryptase antibody (AA1) and/or 1:800 dilution of 
rabbit anti-cytokeratin 8 (ck-8, EP1628Y) for 45 minutes, followed by a cocktail of AP 
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conjugated anti-mouse secondary and HRP-conjugated-anti-rabbit secondary antibody at 
room temperature for 30 minutes. The slides were then treated with DAB (ck-8 positive cells, 
brown) and/or Vector Red (tryptase positive cells, red) for 20 minutes each for visualization.  
 
TMA Sets: 
The following TMA sets were used in the present study: 
 
TMA Set Description 
150 Case Low 
Grade Race 
Disparity 
Radical prostatectomy cohort of 75 AA men matched to 75 CA men 
on age +/- 3 years, grade and stage. Contains primarily Gleason 6 
and 7 tumors. Analyzed both tumor and matched benign tissues. 
338 Case Race 
Disparity 
Radical prostatectomy cohort of 169 AA men matched to 169 CA 
men selected via stratified random sampling among Gleason score 
groupings (3+3, 3+4, 4+3, 8, 9-10). Analyzed both tumor and 
matched benign tissues. Outcomes data available. 
120 Case High 
Grade Race 
Disparity  
Radical prostatectomy cohort of 60 AA men matched to 60 CA men 
on age +/- 3 years, grade and stage. Enriched for cases with Gleason 
≥8. Analyzed both tumor and matched benign tissues.  
 
 
Collection and preparation of rapid autopsy tissues. Metastatic tissues were obtained at 
autopsy, fixed in 10% buffered formalin for 48 hours, and then paraffin embedded and 
sectioned. Bone metastatic samples were decalcified before formalin fixation and embedding.  
 
Scanning and analysis with PIP software. See PIP software development in Chapter II. The 
PIP software was used to measure the number of mast cells per TMA spot (mast cell count or 




Statistical Analysis. A similar approach was taken as outlined in Chapter II. Statistical 
analysis was performed using SAS release 9.4 (SAS Institute, 
Cary, NC) with the analyses indicated in the table legends. 
3.4 Results 
 
We first aimed to determine whether there is a significant difference in mast cell 
number or density in tumor or matched benign prostate tissues from AA and CA men. This 
was accomplished through immunostaining and analysis of three TMA sets: 150 Case Low 
Grade Race Disparity, 120 Case High Grade Race Disparity, and a 338 Case Race Disparity 
(see Methods). There were no significant differences in mast cell density or number in tumor 
or benign tissues in AA men compared to CA men in the 120 Case High Grade Race 
Disparity TMA set (Table 3.1). However, the 150 Case Low Grade Race Disparity TMA set 
showed significantly lower densities of mast cells in tumor tissues in AA men compared to 
CA men, but no differences were observed in mast cell density in benign tissues between AA 
and CA men (Table 3.2). A similar relationship was observed in the 338 Case Race Disparity 
TMA set when stratified by Gleason score; tumors with low Gleason scores (Gleason ≤ 
3+4=7) showed significantly lower mast cell densities in the tumors of AA versus CA men, 
while high Gleason score tumors showed no significant difference (Table 3.3).  
 
Table 3.1. Comparison of mast cell density and count in AA versus CA men in the 120 Case 
High Grade Race Disparity TMA set. 
  
Mast Cell Density 
 




















Minimum Maximum Mean Median STD 
40 
 
CA 60 1.8 4.4 3.2 2.9 1.1 
 
10.0 26.5 19.5 17.8 6.9 
AA 57 2.1 4.2 3.1 3.1 1.0 
 
11.0 24.0 18.3 17.0 5.5 
p  
 
0.6 0.6 0.9 0.9 0.3 
 


















































Minimum Maximum Mean Median STD 
CA 60 1.7 4.7 3.1 3.1 1.3 
 
8.5 25.5 16.9 16.0 6.8 
AA  60 1.8 4.4 3.1 2.9 1.0 
 
9.0 24.0 16.1 14.5 6.2 
p 
 
0.8 0.7 0.8 0.5 0.3 
 

































p: From Wilcoxon signed-rank test 
OR (odds ratio, AA vs. CA): For minimum, odds of falling below first quartile of the respective mast cell measure 
in CA men. For the other measures, odds of falling above third quartile of the respective mast cell measure in CA 
men. Logistic regression model is adjusted for age, stage, grade and surgical margin status. 
Table 3.2. Comparison of mast cell density and count in AA versus CA men in the 150 Case 
Low Grade Race Disparity TMA set. 
  
Mast cell density 
 




















Minimum Maximum Mean Median STD 
CA 75 2.5 4.6 3.4 3.3 1.1 
 
13.0 26.0 19.3 19.0 6.5 
AA 76 1.9 4.1 3.1 2.9 0.9 
 
11.0 24.0 18.0 16.0 5.5 
p 
 
0.1 0.03 0.02 0.02 0.1 
 



















































Minimum Maximum Mean Median STD 
CA 75 1.8 4.0 3.0 3.1 1.0 
 
14.0 21.0 15.5 15.0 5.5 
41 
 
AA 77 1.4 4.1 2.8 2.7 0.9 
 
7.0 20.0 13.8 13.0 4.9 
p 
 
0.1 0.2 0.1 0.03 0.2 
 

































p: From Wilcoxon signed-rank test 
OR (odds ratio, AA vs. CA): For minimum, odds of falling below first quartile of the respective mast cell measure 
in CA men. For the other measures, odds of falling above third quartile of the respective mast cell measure in CA 
men. Logistic regression model is adjusted for age, stage, grade and surgical margin status. Statistically 
significant values are highlighted in red. 
Table 3.3. Comparison of mast cell density and count in AA versus CA men in the 338 Case 
Race Disparity TMA set. 
Gleason=3+
4 or below 
 
 
Mast cell density 
 



















Minimum Maximum Mean Median STD 
CA 72 3.0 5.2 4.0 4.1 1.3 
 
10.0 29.0 22.0 23.3 7.9 
AA 72 2.5 5.5 3.9 3.9 1.4 
 
15.0 31.0 23.8 23.5 8.6 
p 
 
0.05 0.8 0.5 0.4 0.2 
 



















































Minimum Maximum Mean Median STD 
CA 73 2.7 7.1 4.6 4.3 1.6 
 
12.0 33.0 21.8 21.5 7.8 
AA  73 2.3 4.7 3.4 3.5 1.3 
 
10.0 22.0 17.5 17.0 6.4 
p 
 
0.04 0.01 0.01 0.01 0.1 
 


































3 or above 
 
 
Mast cell density 
 



















Minimum Maximum Mean Median STD 
42 
 
CA 74 2.0 5.4 3.6 3.7 1.4 
 
13.0 30.5 20.8 21.0 8.1 
AA 61 2.1 5.0 3.1 3.2 1.5 
 
11.0 31.0 18.0 18.0 9.4 
p 
 
0.9 0.7 0.8 0.8 0.9 
 



















































Minimum Maximum Mean Median STD 
CA 77 2.4 5.1 3.7 3.9 1.2 
 
11.0 26.0 19.3 19.0 6.7 
AA 62 2.4 6.0 4.3 4.2 1.5 
 
10.0 31.0 20.8 19.8 8.6 
p 
 
0.9 0.4 0.5 0.5 0.1 
 

































p: From Wilcoxon signed-rank test 
OR (odds ratio, AA vs. CA): For minimum, odds of falling below first quartile of the respective mast cell measure 
in CA men. For the other measures, odds of falling above third quartile of the respective mast cell measure in CA 
men. Logistic regression model is adjusted for age, stage, grade and surgical margin status. Statistically 
significant values are highlighted in red. 
 
Next, we determined whether mast cell numbers and/or density in prostate tumor and 
benign tissues from AA men had a similar relationship with risk of prostate cancer recurrence 
(PSA progression) as we previously observed (Chapter II), where higher numbers of 
intratumoral mast cells were associated with lower risk of recurrence. Since our previous 
cohort was comprised predominantly of tissues from CA men, we tested our hypothesis using 
the 338 Case Race Disparity TMA set which included outcome data, such as biochemical 
recurrence and development of metastases after radical prostatectomy. The pattern observed 
for low numbers of intratumoral mast cells and biochemical recurrence in the PSA 
Progression TMA set (Chapter II) was present in all strata in both CA and AA men in the 
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present study, although not statistically significant (Table 3.4). Interestingly, these 
associations remained, and appeared even stronger, when development of metastasis was the 
outcome (Table 3.5).  
 
Table 3.4. Adjusted Hazard Ratio* (HR) of prostate cancer biochemical recurrence by race 
and mast cell measurements, 338 Case Race Disparity TMA. 
 
All Tumor Tissue  Benign Tissue 
Minimum Mast 
Cell Density 
Case/Control HR 95% 
CI 
p  Case/Control HR 95% 
CI 
p 
  1(Lowest) 36/29 1    22/36 1   
  2   18/37 0.91 0.48-
1.71 
  24/38 1.13 0.59-
2.15 
 
  3 17/42 0.87 0.45-
1.70 
  29/28 1.13 0.61-
2.10 
 
  4(Highest) 17/28 0.76 0.40-
1.44 
  12/34 0.74 0.35-
1.58 
 
P trend 0.4     0.5 
          
  1(Lowest) 36/29 1    22/36 1   
  2,3 and 4 52/107 0.84 0.51-
1.38 
  65/100 1.02 0.60-
1.76 
 
          
Minimum Mast 
Cell Count 
         
  1(Lowest) 34/28 1    24/34 1   
  2   19/41 0.74 0.40-
1.35 
  22/42 1.05 0.56-
1.99 
 
  3 16/42 0.78 0.39-
1.53 
  30/30 1.06 0.59-
1.91 
 
  4(Highest) 19/25 0.87 0.48-
1.59 
  11/30 0.68 0.32-
1.45 
 
P trend 0.6     0.5 
          
  1(Lowest) 34/28 1    24/34 1   
  2,3 and 4 54/108 0.79 0.49-
1.27 
  63/102 0.96 0.57-
1.61 
 
          





         
  1(Lowest) 21/10 1    12/18 1   
  2   7/24 0.74 0.28-
1.92 
  12/20 1.28 0.54-
3.01 
 
  3 8/25 0.56 0.23-
1.35 
  15/17 1.13 0.48-
2.68 
 
  4(Highest) 12/19 0.72 0.33-
1.59 
  9/22 1.15 0.46-
2.87 
 
P trend 0.3     0.8 
          
  1(Lowest) 21/10 1    12/18 1   
  2,3 and 4   27/68 0.67 0.35-
1.28 
  36/59 1.19 0.58-
2.43 
 
          
Minimum Mast 
Cell Count 
         
  1(Lowest) 12/20 1    12/19 1   
  2   7/26 0.66 0.26-
1.68 
  14/22 1.50 0.67-
3.37 
 
  3 8/24 0.52 0.22-
1.26 
  14/16 1.08 0.46-
2.54 
 
  4(Highest) 13/16 0.97 0.46-
2.06 
  8/20 1.11 0.44-
2.85 
 
P trend 0.7     0.9 
          
  1(Lowest) 12/20 1    12/19 1   
  2,3 and 4   28/66 0.72 0.39-
1.35 
  36/58 1.24 0.61-
2.51 
 
          
AA          
Minimum Mast 
Cell Density 
         
  1(Lowest) 15/19 1    10/18 1   
  2   11/13 0.98 0.35-
2.79 
  12/18 0.98 0.36-
2.66 
 
  3 9/17 1.20 0.41-
3.53 
  14/11 1.13 0.39-
3.32 
 
  4(Highest) 5/9 0.96 0.30-
3.11 
  3/12 0.55 0.13-
2.39 
 
P trend 0.9     0.6 
          
  1(Lowest) 15/19 1    10/18 1   
45 
 
  2,3 and 4   25/39 1.04 0.44-
2.45 
  29/41 0.94 0.38-
2.34 
 
          
Minimum Mast 
Cell Count 
         
  1(Lowest) 14/16 1    12/15 1   
  2   12/15 0.74 0.29-
1.91 
  8/20 0.61 0.19-
1.95 
 
  3 8/18 1.15 0.35-
3.80 
  16/14 1.14 0.46-
2.85 
 
  4(Highest) 6/9 0.87 0.30-
2.49 
  3/10 0.52 0.12-
2.20 
 
P trend 0.9     0.8 
          
  1(Lowest) 14/16 1    12/15 1   
  2,3 and 4   26/42 0.85 0.38-
1.86 
  27/44 0.86 0.37-
2.04 
 
*, adjusted for age, race (only for all), grade, stage, PSA and BMI. 
 
Table 3.5. Adjusted Hazard Ratio* (HR) of prostate cancer metastasis by race and mast cell 
measurements, 338 Case Race Disparity TMA. 
 
All Tumor Tissue  Benign Tissue 
Minimum Mast 
Cell Density 
Case/Control HR 95% 
CI 
p  Case/Control HR 95% 
CI 
p 
  1(Lowest) 15/50 1    8/50 1   
  2   8/47 1.43 0.48-
4.23 
  9/53 0.79 0.26-
2.43 
 
  3 6/53 0.73 0.23-
2.31 
  8/49 0.72 0.22-
2.40 
 
  4(Highest) 1/44 0.14 0.02-
1.06 
  5/41 0.87 0.25-
3.05 
 
P trend 0.05     0.8 
          
  1(Lowest) 15/50 1    8/50 1   
  2,3 and 4 15/144 0.65 0.28-
1.47 
  11/143 0.79 0.30-
2.07 
 
          
Minimum Mast 
Cell Count 
         
  1(Lowest) 15/47 1    10/48 1   
  2   8/52 0.86 0.30-
2.44 





  3 6/52 0.72 0.22-
2.37 
  8/52 0.79 0.27-
2.28 
 
  4(Highest) 1/43 0.11 0.01-
0.85 
  4/37 0.71 0.20-
2.52 
 
P trend 0.02     0.5 
          
  1(Lowest) 15/47 1    10/48 1   
  2,3 and 4 15/147 0.51 0.22-
1.15 
  20/145 0.81 0.34-
1.94 
 
          
CA          
Minimum Mast 
Cell Density 
         
  1(Lowest) 10/21 1    4/26 1   
  2   2/29 0.96 0.19-
4.96 
  4/28 1.18 0.25-
5.57 
 
  3 4/29 0.90 0.26-
3.17 
  5/27 1.32 0.27-
6.48 
 
  4(Highest) 1/30 0.18 0.02-
1.52 
  4/27 1.54 0.32-
7.30 
 
P trend 0.2     0.6 
          
  1(Lowest) 10/21 1    4/26 1   
  2,3 and 4   7/88 0.67 0.35-
1.28 
  13/82 1.34 0.36-
5.02 
 
          
Minimum Mast 
Cell Count 
         
  1(Lowest) 10/22 1    4/27 1   
  2   2/31 0.64 0.12-
3.32 
  5/31 1.76 0.42-
7.44 
 
  3 4/28 0.90 0.25-
3.24 
  5/25 1.82 0.40-
8.27 
 
  4(Highest) 1/28 0.15 0.02-
1.32 
  3/25 1.30 0.25-
6.73 
 
P trend 0.1     0.7 
          
  1(Lowest) 10/22 1    4/27 1   
  2,3 and 4   7/87 0.50 0.18-
1.41 
  13/81 1.64 0.46-
5.78 
 
          
AA          
Minimum Mast 
Cell Density 
         
47 
 
  1(Lowest) 5/29 1    4/24 1   
  2   6/18 3.74 0.42-
33.48 
  5/25 1.45 0.09-
23.60 
 
  3 2/24 -    3/22 0.21 0.01-
5.47 
 
  4(Highest) 0/14 -    1/14 0.75 0.03-
17.63 
 
P trend 0.1     0.4 
          
  1(Lowest) 5/29 1    4/24 1   
  2,3 and 4   8/56 1.01 0.12-
8.41 
  9/61 0.62 0.07-
5.86 
 
          
Minimum Mast 
Cell Count 
         
  1(Lowest) 5/25 1    6/21 1   
  2   6/21 1.26 0.17-
9.61 
  3/25 0.25 0.02-
3.20 
 
  3 2/24 -     3/27 0.11 0.004-
2.80 
 
  4(Highest) 0/15 -     1/12 0.16 0.01-
4.68 
 
P trend 0.1     0.2 
          
  1(Lowest) 5/25 1    6/21 1   
  2,3 and 4   8/60 0.42 0.06-
3.04 
  7/64 0.18 0.02-
1.81 
 
*, adjusted for age, race (only for all), grade, stage, PSA and BMI. 




Due to the unexpected finding that revealed a relationship between low mast cell 
numbers and the development of metastases after radical prostatectomy in the present study, 
we next determined whether prostate cancer metastases contained high or low densities of 
intratumoral mast cells. Rapid autopsy tissues from three prostate cancer patients were 
immunostained for tryptase and evaluated. Interestingly, for prostate, lung, and liver 
metastatic tissues, no intratumoral mast cells were seen infiltrating the tumor (Figure 3.1). 
However, infiltrating intratumoral mast cells were present in bone metastasis.  
 
 
Figure 3.1. IHC for mast cell tryptase in a cohort of rapid autopsies from men with 
prostate cancer. A) Prostate cancer in a prostate at time of autopsy (40X). No 
intratumoral mast cells (red staining cells) are observed within tumor foci (arrows). B) 
Prostate cancer lung metastasis (arrow) at 200X with no intratumoral mast cells. C) 
Prostate cancer bone metastasis at 100X with infiltrating intratumoral mast cells. D) 




 3.5 Discussion and Conclusions 
Given our previous results outlined in Chapter II, there is evidence to suggest that 
mast cells may be an indicator of cancer aggressiveness and/or recurrence. As African 
American men have been shown to be more likely to develop aggressive prostate cancer and 
to recur at a higher rate than Caucasian American men, as well as present with higher levels 
of inflammation, there was reason to study the role of mast cells race disparities in prostate 
cancer 86,87. We aimed to address several questions to determine if mast cells are contributing 
factors in prostate cancer race disparities. First, do prostate tumor and benign tissues from 
AA men contain similar numbers and density of mast cells inside and outside the tumor 
compared to CA men? Secondly, do mast cells have the a similar relationship with risk of 
recurrence (PSA progression) in AA men as we previously observed; specifically, that low 
numbers of intratumoral mast cells correlate with higher risk of recurrence? 
The first question was pursued by immunostaining and analysis of three cohorts 
represented on TMAs consisting of tumor and benign tissues from AA and CA men. Overall, 
the results showed no significant difference in mast cell number or density in tumor or 
benign tissues between AA and CA men, except when stratified by low versus higher 
Gleason grade (Tables 3.1-3.3). Tumors from AA men had significantly lower densities of 
mast cells compared to tumors of CA men, specifically in lower Gleason grade (Grade 6-7) 
tumors (Table 3.2, 3.3). The lack of difference in the higher Gleason scores may be due to 
the fact that the AA cases were matched to the CA cases on tumor grade and stage. 
Therefore, if mast cell density is truly associated with risk of recurrence in AA as well as CA 
men, then the mast cell densities would be similar. In retrospect, it may be better to 
determine whether AA men have lower densities of mast cells compared to CA men in a 
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cohort that is not closely matched on clinical parameters. Unfortunately, we did not have 
access to such a cohort, and performed our analysis in the available TMAs. 
The second question was whether mast cells have the same relationship with PSA 
progression in AA men as they do in CA men. This question was studied in a high risk AA 
TMA with associated outcome data. When mast cell density was studied in relation with risk 
of recurrence, the results, though not significant, followed a similar trend as in Chapter II 
(Table 3.4). Interestingly, when we assessed the association of mast cell number and density 
with the development of metastases, we observed that low numbers of mast cells were 
significantly correlated with the development of metastases (Table 3.5). These results were 
also intriguing in light of our immunostaining results in metastatic lesions (Figure 3.1), 
where in all tissues except for bone, mast cells were not seen to be infiltrating the tumor.  
As AA men are known to be more likely to develop metastasis and often present with 
an aggressive prostate cancer, it is possible that the AA men with lower grade tumors 
(Gleason 7) at radical prostatectomy will eventually go on to experience a biochemical 
progression and/or metastasis, thereby explaining the difference. This should certainly be the 
focus of future follow up studies. 
 
IV. MAST CELL PHENOTYPING IN PROSTATE CANCER VERSUS BENIGN 
PROSTATE TISSUES  
4.1 Abstract 
Our previous studies suggest that mast cells have a differential relationship with 
prostate cancer prognosis depending on whether they are present inside or outside the tumor. 
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As such, in the present study, we questioned whether mast cells or their immediate 
microenvironments were phenotypically different based on whether they were present within 
cancerous or benign regions of the prostate. As an initial approach, we used IF assays to 
determine the mast cell subtype ratios in tumor and benign tissues via the expression of 
chymase, a protease that has been traditionally used to differentiate between the two classical 
subtypes of mast cells, MCtc, and MCt. We further used a toluidine blue stain and LCM 
technique to enrich for mast cells and their nearest interacting cells from frozen tumor and 
benign prostate tissues. RNAseq was performed for expression analysis of the samples, and 
multiple genes of interest from this dataset were chosen for further validation. An isoform of 
C-kit, C-kit Variant 1, was found to be more highly expressed in mast cells located in benign 
tissue versus tumor-infiltrating mast cells, a relationship corroborated by PCR-based 
techniques. C-X-C chemokine receptor type 4 (CXCR4) and Transcription Factor Binding To 
IGHM Enhancer 3 (TFE3), both of which are associated with mast cell activation, were 
found to be more highly expressed in tumor-associated than benign prostate tissue mast cells. 
This expression pattern was verified via in situ hybridization techniques, which indicated that 
expression of CXCR4 and TFE3 are increased in multiple cell types within tumor and 
inflamed regions. These results indicate that prostate tumor-infiltrating mast cells are 
phenotypically different from benign tissues mast cells and support the hypothesis that mast 









As seen in both Chapters II and III, our studies suggests mast cells have a differential 
relationship with prostate cancer prognosis depending on whether they are found within or 
outside the tumor. Given this differential relationship between mast cells number/density and 
biochemical recurrence and/or metastases based on mast cell geographical location, we 
aimed to determine whether mast cells or their immediate microenvironment are biologically 
different inside versus outside the tumor as a potential factor in their dichotomous 
relationship.  
As discussed in Chapter I, mast cells originate in the bone marrow and undergo their 
final differentiation in their final tissue 1,7. This differentiation can be between the two 
classical subtypes, MCtc and MCt, or between more subtle differences between protease and 
effector molecular expression profiles 3,7,26,27. In addition, there is mounting evidence that 
mast cell profiles within the microenvironment are not final, either by mast cell plasticity or 
by recruitment of mast cell precursors that eventually develop into different subtypes based 
on signals in the microenvironment 1,28,29,121. In one study, mast cell markers were studied in 
patients with and without severe asthma in order to analyze changes in mast cell subtype 121. 
Endobronchial biopsies, epithelial brushings, and bronchoalveolar lavage samples were 
analyzed with IHC and qPCR techniques for total mast cell number and mast cell subtype to 
obtain a MCtc/total mast cell (Mctot) ratio121. Results showed that MCtc/MCtot was 
increased in severe asthma compared to mild asthma/no inhaled corticosteroid treatment 
group 121. These results, in addition to other studies, suggest that the mast cell profile in the 
disease microenvironment can shift 118,121. As such, there is ample reason to suggest that 
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expression profiles of mast cells within or outside the tumor would be different. In addition, 
it stands to reason that interactions between those mast cells and other cells in the 
microenvironment would also change. 
Mast cells interact with many cells in the tissue microenvironment, including 
inflammatory cells, fibroblasts, and epithelial cells. Mast cells are known to interact with 
neutrophils, B cells, T cells, Tregs, and NK cells 1,122. Mast cells can also produce cytokines 
promoting angiogenesis and cancer cell proliferation 27,39-41,113. Finally, mast cells are well 
known to interact with fibroblasts, where fibroblasts produce a number of factors capable of 
influencing, regulating, and recruiting mast cell activity 106. As such, we hypothesized the 
immediate microenvironments and cells directly interacting with mast cells within and 
outside the tumor may differ. 
In order to explore the biology behind the dichotomous relationship between tumor 
and benign tissue mast cells, we identified and isolated matched tumor-infiltrating and 
benign tissue mast cells from frozen prostate tissues via LCM and conducted RNAseq 
experiments. The results of these studies indicated that the gene expression profile of tumor-
infiltrating mast cells is vastly different from that of benign tissue mast cells. Four markers of 
interest were chosen for validation via quantitative PCR (qPCR) and RNA in-situ 
hybridization techniques, namely C-kit variants 1 and 2, CXCR4, and TFE3 variant 2, all of 
which are associated with mast cell activation. 
 
4.3 Methods 
Tryptase-Chymase double IF. TMAs were treated with HTTR antigen retrieval followed by 
incubation with anti-chymase antibody (Abcam ab18617 mouse-raised, 1:2000) and anti-
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tryptase antibody (Abcam Ab2378 rabbit-raised, 1:2000). Antigen detection was 
accomplished with goat-ant-rabbit Cy3 secondary and chicken-anti-mouse Cy5 secondary 
(A11036 and A21463 respectively, both 1:100), as well as treatment with DAPI for nuclear 
visualization.  
 
Toluidine blue staining and LCM. Frozen tumor and matched benign prostate tissues from 4 
radical prostatectomy specimens (all Gleason grade 9) were cut onto Leica PEN-membrane 
4,0um Frame slides, fixed in 90% ethanol in DEPC, and toluidine blue stained with 0.1% 
toluidine blue (Sigma) in DEPC treated with 0.4U/uL Protector RNase Inhibitor (ref. 
03335402001). LCM was performed on the Leica LMD 7000 Microscope.   
 
RNA extraction and RNAseq. RNA extraction was accomplished with Qiagen RNeasy Micro 
Kit. Tumor and benign mast cell RNA samples were pooled for each case (resulting in one 
pooled tumor sample and one pooled benign sample), RNA quality was assessed using a 
Bioanalyzer, and RNA sequencing (RNAseq) was performed at the Sidney Kimmel 
Comprehensive Cancer Center Next Generation Sequencing Core Facility.  
 
C-kit variant 1 qPCR and RT-PCR. qPCR was performed with C-kit variant 1 forward primer 
5’-CAACAAAGAGCAAATCCATCCC-3’ and reverse primer  5’-
CATCACAATAATGCACATCATGCC-3’ with iQ SYBR Green supermix (Cat. No. 
1708882). The PCR program was as follows: 94oC for 3 min followed by 40 cycles of 94oC 
for 30 seconds, 50oC for 30 seconds and 72oC for 30 seconds. RT-PCR and KIT variant 
genotyping was performed with C-kit forward primer 5’-CAGCAAGGAGTGAACAG-3’ 
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and reverse primer 5’-GGGGGATCCGATGTGGGAAGACTTCT-3’. The program was as 
follows: 94oC for 3 min followed by 40 cycles of 94oC for 30 seconds, 50oC for 30 seconds 
and 72oC for 30 seconds, finished with 72oC. Products were run on a 4% gel. 
 
Control cell plugs for Kit V1 and V2, CXCR4, TFE3.  Control cell plugs were made by 
transfection of PC3 cells with C-kit Variant 1 human ORF cDNA clone (Origene 
NM_000222), C-kit Variant 2 human ORF cDNA clone (Origene NM_001093772), CXCR4 
human ORF cDNA clone (Origene NM_003467), TFE3 variant 2 human ORF cDNA clone 
(Origene NM_001282142). Transfection was accomplished with Lipofectamine 2000 (Life 
Technologies L0000-001). Cells were spun down, fixed in 10% formulin at least 48hrs, and 
paraffin embedded.  
 
RNA in situ hybridization (RISH). 1zz probes were designed by Advanced Cell Diagnostics 
(ACD) to be specific to c-kit variant 1 but not variant 2. The Basescope manual red kit was 
used to stain C-kit variant 1, variant 2, and no-plasmid control transfected cell plugs with 
variant 1 and 1zz PPIB probes. Staining of control plugs was also done with DNAse I 
(bovine Sigma Cat# D5319) or RNAse A (DNAse-free Affymetrix #78020Y) treatment steps 
to verify detection of RNA versus genomic DNA. The ACD RNAscope 2.5 manual brown 
kit was used to stain CXCR4 transfected and no plasmid control cell plugs with CXCR4 
probe (ACD Cat# 310511), and TFE3-transfected and no-plasmid control cell plugs with 
TFE3 probe (Cat. No. 430461). ACD Dual RNAscope manual kit was used to double stain 
FFPE TMA 1170 for C-kit (Cat No. 606401)-CXCR4 (Cat No. 310511-C2), CXCR4 (Cat 
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Mast cell subtyping using IF for tryptase and chymase. As an initial assessment of mast 
cell subtypes in relation to prostate cancer, we used a dual IF stain to analyze the 120 Case 
High Grade Race Disparity TMA set (see Chapter III) to determine if there was a difference 
in mast cell subtype ratios between tumor and benign tissues in relation to tumor grade or 
stage and in AA and CA men. As shown in Figure 4.1, MCt cells were visualized as tryptase 
only positive mast cells and MCtc cells were visualized as tryptase and chymase double 
positive mast cells.                
 
Figure 4.1 Dual IF for mast cell tryptase (green) and chymase (red). Left, TMA 
visualized by IF. Right, individual TMA spot showing mast cell subtypes visualized using 
dual IF, where total mast cells (MCtot) were all tryptase positive cells, MCtc were tryptase 
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and chymase double positive cells (arrow denoted as MTC), and MCt were MCtot-MCtc 
tryptase only positive cells (arrow denoted as MT).  
 
We used automated image analysis software from TissueGnostics which is designed for 
image analysis of fluorescent images to identify and count the number of MCt and MCtc in 
each tissue spot represented across the TMAs. As with the PIP software that we used for 
chromogenic assessment of mast cells (see Chapters II and III), we began by comparing the 
automated counting to manual counting as the gold standard. We found a high correlation 
between manual counting and automated counting using the TissueGnostics software (R2 = 





Figure 4.2. Comparison of manual vs TissueGnostics automated count of MCtot and 
MCtc in the 120 Case Race Disparity TMA. Comparison shows that TissueGnostics 
software provides an accurate count of both MCtot (A) and MCtc (B), with R2 values of 0.94 
and 0.93, respectively.       
  
Interestingly, the results of these analyses indicated that there is a significantly greater 
proportion of MCt (tryptase-only mast cells) in prostate cancer compared to matched benign 
tissues and likewise a significantly greater proportion of MCtc (tryptase and chymase 
positive mast cells) in benign regions compared to cancer regions (Table 4.1). However, 
there were no differences found in MCt or MCtc mast cell subtypes between the AA and CA 
men in this cohort (Table 4.2). 
Table 4.1.  Paired comparison of mast cell subtype ratios between tumor and benign tissues in the 
120 Case Race Disparity TMA set. 
   
 Ratio* of Tryptase Only N Minimum Maximum Mean Median STD*** 
    Tumor 117 0.41 0.90 0.68 0.69 0.15 
    Benign 117 0.27 0.92 0.58 0.58 0.19 
    p**  0.0002 0.7 0.02 0.03 <.0001 
       
Ratio of Tryptase_Chymase       
    Tumor 117 0.10 0.59 0.32 0.31 0.15 
    Benign 117 0.08 0.73 0.42 0.42 0.19 
    p**  0.7 0.0002 0.02 0.03 0.05 
* Ratio=subtype mast cell count/total mast cell count 
** p: Paired comparison using Wilcoxon signed-rank test 
*** N=111 
 






Tumor Tissue N Minimum Maximum Mean Median STD 
CA 59 0.1 0.6 0.3 0.3 0.1 
AA 59 0.04 0.6 0.3 0.3 0.2 
p**  0.7 0.8 0.9 0.9 0.9 











       
Normal Tissue       
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CA 60 0.05 0.7 0.4 0.3 0.2 
AA 60 0.1 0.8 0.4 0.4 0.2 
p  0.3 0.3 0.2 0.1 0.5 











       
Ratio of Tryptase_Only  
      
Tumor Tissue       
CA 59 0.4 0.9 0.7 0.7 0.1 
AA 59 0.4 1.0 0.7 0.7 0.2 
p   0.8 0.7 0.7 0.9 0.9 










       
Normal Tissue       
CA 60 0.3 1.0 0.6 0.7 0.2 
AA 60 0.2 0.9 0.6 0.6 0.2 
p  0.3 0.3 0.2 0.1 0.5 










* Ratio=subtype mast cell count/total mast cell count 
** p: From Wilcoxon signed-rank test 
*** OR (odds ratio, AA vs. CA): For minimum, odds of falling below first quartile of the respective 
mast cell measure in CA men. For the other measures, odds of falling above third quartile of the 
respective mast cell measure in CA men.  Logistic regression model is adjusted for age, stage, grade 
and surgical margin status.  
 
Gene expression analysis of tumor-infiltrating and benign tissue mast cells. Toluidine 
blue staining of frozen tissues both allowed for visualization of mast cells in purple against 
the blue counterstain (Figure 4.3) as well as preservation of the mRNA from the cells 
collected. Separately, we collected mast cells from tumor and benign regions from four cases, 
extracted RNA, and performed RNAseq. The RNAseq data identified reads from 9,041 
different genes expressed in these samples. Of these genes, 1,457 were at least 3-fold greater 
in transcripts per kilobase million (TPM) in tumor mast cells versus benign and 2,561 genes 
were 3-fold greater in TPM in benign tissue mast cells versus tumor. Importantly, there was a 
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strong representation of mast cell related genes (Table 4.3), supporting the conclusion that 
mast cell enrichment was achieved. Important genes that identify mast cells such as tryptase 
subunits alpha/beta1, beta 2, and gamma 1, as well as C-kit, chymase, VWASA, and 
GATA2, were found to have no significant differences in expression between the two groups. 
Other genes, however, were found to be different, with CD44 being more highly expressed in 
mast cells isolated from benign tissues, and CXCR4 and TFE3 being more highly expressed 
in mast cells isolated from tumor tissues.  
 
Figure 4.3. Image of toluidine blue staining and LCM for enrichment of mast cells and 
the immediate microenvironment. Mast cells and nearby nuclei were successfully isolated 
via LCM. 
 
Genetic isoforms were also analyzed for differences in expression between tumor and benign 
tissue mast cells. One gene of particular interest was C-kit, and its’ isoforms 1 and 2. 
Although overall C-kit expression was the same in tumor and benign (Table 4.3), C-kit 
Variant 1 was more highly expressed in benign tissue mast cells, while C-kit variant 2 was 










Table 4.3. Select genes identified in tumor and benign tissue mast cells via RNAseq. 
There were a high number of mast cell-related genes identified in the RNAseq data, 
validating that mast cells were successfully enriched via LCM. Genes highlighted in green 
were more highly expressed (> 3 fold) in tumor mast cells, yellow were similarly expressed 
in tumor and benign, and red were more highly expressed (> 3 fold) in benign. Two genes 
that were highly differentially expressed between tumor and benign tissue mast cells are 
TFE3 and CXCR4. 
 
 
prob – probability of differential expression  
 
Table 4.4. C-kit variants 1 and 2 show differential expression in tumor compared to 
benign tissue mast cells. Although overall C-kit (KIT) expression was roughly equivalent 
between tumor and benign, there was differential expression of C-kit variants, with Variant 1 
showing higher expression in benign, and Variant 2 showing higher expression in tumor. 
 
Gene prob log2(B9/cancer)  TPM Benign TPM Cancer Notes
TFE3 1.00 -15.23 0.00 26432.08 Potential regulator of mast cell functions (PMID 22360977)
RSBN1 1.00 -13.63 2.14 35950.60
CXCR4 1.00 -12.48 2.14 16149.36 Expressed within the mast cell lineage and its ligand SDF-1alpha/CXCL12 acts as a mast cell chemotaxis
ARHGAP5 1.00 -12.33 10.70 58521.43 Upregulated in mast cells in response to infection with live streptococci (PMID 19933827)
ICMT 1.00 -11.54 11.00 34751.87
MMP24 1.00 -9.55 0.00 519.65 Involved in cell-cell interactions between nociceptive neurites and mast cells (PMID 19805319)
STAT3 1.00 -8.95 2.15 1402.82
KMT2A 1.00 -8.78 251.99 111413.54 mutated in systemic mastocytosis (PMID 25305106)
CXCL12 1.00 -8.37 0.00 229.90
PTPN11 1.00 -7.389 0.54 205.6 Positively regulates KIT, required for mast cell survival and homeostasis, promotes chemotaxis (PMC4383135)
CD74 1.00 -6.96 28.36 3620.46 Complexes with CXCR4, receptor for MIF (PMID 19665027)
TPSD1 1.00 -6.92 3.75 535.27 Tryptase delta 1
VWA5A 0.64 -3.56 3837.21 45255.96 Mast cell surface antigen 1
FCER1A 0.70 -3.06 272.86 2284.03 IgE receptor subunit alpha
TPSAB1 0.17 -1.52 3138.91 8977.96 Tryptase alpha/beta 1
MALAT1 0.03 -0.74 169451.36 282588.33
HPGDS 0.14 -0.74 3371.14 5618.57 Catalyzes conversion of PGH2 to PGD2 and plays a role in the production of prostanoids in mast cells
CPA3 0.09 -0.65 10456.93 16433.19 Mast cell carboxypeptidase A
HRH4 0.64 -0.62 3.41 5.61 Histamine receptor H4
KIT 0.11 -0.52 6254.21 8950.15 Mast/stem cell growth factor receptor
TGFBR2 0.20 -0.44 929.31 1263.51 Receptor for LRG1, may be a key regulatory factor of allergic responses (PMID 27378305)
LRG1 0.34 -0.43 155.40 210.12 Ligand for TGFBR2, may be a key regulatory factor of allergic responses (PMID 27378305)
TPSB2 0.20 0.56 1746.96 1181.14 Tryptase beta 2
HDC 0.15 1.25 11114.64 4661.55 Histidine decarboxylase
CMA1 0.43 1.51 399.12 140.18 Chymase
STX3 0.32 1.84 2175.62 607.46 Controls distinct essential steps in mast cell degranulation (PMID 24323579)
TPSG1 0.76 2.32 2.79 0.00 Tryptase gamma 1
IL1RL1 0.44 2.90 4577.46 613.07 IL1RL1/ST2 gene encodes receptor for IL-33 (modulator of Th2) in mast cells (PMID 22865859)
GATA2 0.50 3.32 6476.36 648.58 Critical for mast cell differentiation and maintenance (PMID 25801432)
HRH1 0.83 3.35 82.72 7.48 Histamine receptor H1
CD44 0.79 5.29 18053.72 459.80 Involved in mast cell proliferation and terminal differentiation (PMID 19204665)
DUSP1 0.93 6.34 7145.33 87.85 May modulate mast cell activation and allergic reaction (PMID 17636038)
CERK 0.98 7.18 100.12 0.00 Mediator of calcium-dependent degranulation in mast cells (PMID 14769792)
LTB4R 0.99 7.47 452.62 1.87 Recruitment of mast cells in response to LTB4 production in areas of inflammation (PMID 16920986)
IL15 0.99 8.26 1358.77 3.74 Controls mast cell survival and homeostasis (PMID 19632221), suppresses chymase activities (PMID 17643110)
MRGPRX2 0.99 8.55 256.81 0.00 Controls secretagogue-induced histamine release (PMID 25517090)
IGF1 0.99 8.80 9499.62 20.65 Promotes mast cell survival (PMID 17046573)





We chose to pursue validation of differential expression of C-kit variant 1, CXCR4, and 
TFE3 in tumor and benign tissue mast cells, as well as determine the localization of the 
expression of these genes in the tumor microenvironment. 
C-kit variant 1 expression analysis. PCR primers designed against the C-kit variant 1 
region that is absent in variant 2 were used to perform reverse transcription qPCR on mRNA 
collected from prostate tumor and matched benign tissues. The RNA samples were from 
harvested frozen prostate tissues (not LCM isolated mast cells) from a range of Gleason score 
tumors and their adjacent benign prostate tissues. In all cases, expression of C-kit variant 1 
was higher in RNA from benign tissues than in the matched tumor tissue RNA (Figure 4.4).  
In addition, primers designed to detect both C-kit variant 1 and variant 2 mRNA were used to 
perform reverse transcription PCR (RT-PCR) and the products run on a 4% agarose gel to 
detect both variants simultaneously in the same RNA samples (Figure 4.5). These primers 
were found to preferentially amplify variant 2 over variant 1 when using equal amounts of 
plasmid DNA containing each C-kit variant (data not shown), so the data were not 
quantifiable. This experiment did, however, serve to confirm the presence of both gene 
isoforms in both tumor and benign tissue RNA samples in this sample set. 
Finally, we designed an in situ hybridization probe that was specific to C-kit variant 1 using 
the BaseScope assay from Advanced Cell Diagnostics. We validated the specificity of the 
probe using PC3 cells transfected with expression vectors containing C-kit variant 1 or 2 
(Figure 4.6). An analysis of a small TMA set containing tumor and matched benign tissues 
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from 5 radical prostatectomy specimens showed that C-kit variant 1 expressing mast cells 
were often found in benign regions of the prostate as opposed to cancer (Figure 4.6). 
 
 
Figure 4.4. qPCR for C-kit Variant 1. Across Gleason scores, benign tissue had higher 






Figure 4.5. RT-PCR verification of the presence of both C-kit variants in tumor and 
matched benign prostate mRNA. The PCR primers were found to preferentially amplify 
Variant 2, so the data is not quantitative and direct comparison of expression levels cannot be 






Figure 4.6. Visualization of c-kit variant 1 using RISH. A) Validation of the variant 1 
(V1) probe set in variant 1 or variant 2 transfected PC3 cells. B) Basescope RISH assay for 
1zz PPIB (red chromogen, positive control, C), RISH for c-kit (all variants, brown 
chromogen, and D) Basescope RISH for c-kit variant 1 (red chromogen). C-kit positive mast 
cells (arrows) are present in all regions as seen in panel C, but c-kit V1 expressing mast cells 
(arrows) are only present in benign regions in panel D. 
 
Visualization of CXCR4 expression using RISH. RNAscope probes designed against 
CXCR4 mRNA were validated via the transfection of CXCR4 plasmid into PC3 cells and 
treatment with the RNAscope 2.5 brown kit. PPIB RNA quality positive controls showed 
high quality RNA, and the CXCR4 probe was specific to the cell plug transfected with the 
CXCR4 expression vector (Figure 4.7). CXCR4 RISH on prostate tissues showed limited 
CXCR4 expression in normal appearing prostate tissues and much higher levels of CXCR4 
expression in areas with cancer and areas with inflammation (Figure 4.8). The positive 
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CXCR4 signals were primarily present in the stromal compartment and appeared to be in 
inflammatory cells. Dual in situ hybridization was performed to elucidate if CXCR4 
expression was found mainly in mast cells or in other inflammatory cells. The results showed 
that, although some positive mast cells could be seen (Figure 4.9), a large number of the 
positive inflammatory cells were likely lymphocytes, many of which could be seen in close 
proximity to mast cells. Many CXCR4 positive macrophages were also identifiable in the 
tumor microenvironment (Figure 4.9).  
 
 
Figure 4.7. PPIB (positive control) and CXCR4 RISH on transfected cell plug controls. 





Figure 4.8. CXCR4 in situ hybridization in prostate tissue. CXCR4 (brown staining) 





Figure 4.9. Dual in situ hybridization demonstrating CXCR4+ mast cells, CXCR4+ 
lymphocytes, mast cells in close proximity to CXCR4+ lymphocytes, and CXCR4+ 
macrophages. A) Presence of mast cells (arrows) double positive for C-kit (green) and 
CXCR4 (red). B) Presence of a cluster of lymphocytes (arrow) positive for CXCR4 (red). C) 
67 
 
C-kit+ mast cells (green) were seen to be in close proximity to CXCR4+ (red) inflammatory 
cells (arrows). D) Macrophages (arrows) double positive for CD68 (red) and CXCR4 (green). 
 
Visualization of TFE3 expression using RISH. Visualization of TFE3 expression patterns 
via RNAscope RISH showed abundant expression of TFE3 in stromal and epithelial cells in 
both tumor and benign prostatic tissue. However, in benign tissue, mast cells were rarely 
observed in close proximity to TFE3 positive cells, while this was commonly observed 
between mast cells and TFE3 positive stromal cells in the tumor microenvironment (Figure 
4.10). Occasional TFE3 and C-kit double positive mast cells were observed in tumor areas 




Figure 4.10. Dual in situ hybridization of TFE3 (green) and C-kit (red). TFE3 expression 
is present in both tumor and benign stromal and epithelial cells. However, A) TFE3 positive 
mast cells and mast cells associated with TFE3 positive cells occurred more frequently in B) 
tumor than in C) benign.  
 
4.5 Discussion and conclusions 
In previous studies, mast cells have been seen to have a differential relationship with 
risk of recurrence depending on whether they are intra- or extratumoral mast cells115,120. As 
such, there is evidence to suggest a potential difference in biology either within the mast cells 
themselves, or in the microenvironment interactions with those mast cells. Consequently, we 
sought to both enrich for mast cells inside or outside the tumor, as well as the immediate 
cellular microenvironment in direct contact with those mast cells. LCM proved to be an 
effective method to accomplish those goals, offering the additional benefits of minimal 
manipulation of the mast cells and the ability to be specific as to whether they were located 
in tumor or benign regions of the prostate. 
Since mast cell expression profiles are potentially subject to the microenvironment, 
the use of other methods of enrichment, such as the use of antibodies for mast cell isolation, 
could have affected the results of the study. Importantly, isolating mast cells from 
homogenized tissue would have limited our ability to differentiate between intra- and extra-
tumoral mast cells. Consequently, we chose a method that allowed direct visualization of the 
mast cells in situ with limited treatment and effects of sample manipulation on RNA 
expression. Toluidine blue stain and LCM proved to be an effective method for mast cell 
enrichment, as evidenced by the identification of numerous mast cell-related genes in the 
RNAseq data (Table 4.3).  
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LCM also allowed for the inclusion of immediately adjacent epithelial, stromal, and 
inflammatory cells. We found this to be a strength, as we were interested not only in the mast 
cell phenotypes, but their immediate interactions with their microenvironments. However, 
the strong presence of a large number of mast cell associated genes provides evidence that 
mast cells were enriched.  
The mast cell-related genes identified by RNAseq included Tryptase, Chymase, C-kit, 
CXCR4, GATA2, TFE3, and GATA2 (see Table 4.3). Some of these genes showed no 
significant difference between tumor and benign mast cells, such as tryptase, chymase, and 
C-kit, which would be expected for mast cell marker genes. One gene of particular interest 
seen to be increased in benign prostate mast cells compared to tumor-infiltrating mast cells 
was C-kit variant 1, while several genes of interest were more highly expressed in tumor-
infiltrating mast cells than benign, including CXCR4, and TFE3. 
Although overall C-kit expression was roughly equivalent in tumor and benign, there 
was significant differences in the expression of C-kit variants in tumor compared to benign, 
where C-kit variant 1 was higher in benign tissue mast cells and variant 2 was higher in 
tumor-infiltrating mast cells. C-kit variant 1 is expressed in lower levels than variant 2, 
especially in the context of cancer, and variant 2 differs from variant 1 by the absence of 12 
base pairs via an in-frame splice site variation 123,124. Variant 2 has been shown in multiple 
studies to be associated with higher colony formation, lower contact inhibition, and higher 
tumorigenicity in mice when expressed in NIH3T3 fibroblasts 123. Expression of variant 2 in 
early myeloid cells also results in higher and more rapid activation and internalization of 
SRC family kinases in response to SCF, as well as higher SCF-dependent growth and a 
stronger chemotactic response to SCF in-vitro compared to early myeloid cells expressing 
70 
 
variant 1 125. In addition, variant 2 has been associated with higher levels of granule 
formation, histamine content, and growth in mast cells as well as in faster response to SCF 
compared to variant 1, however variant 1 expression resulted in longer activation 126,127. 
Finally, a higher serum variant 2/variant 1 ratio has also been associated with higher levels of 
neoplastic mast cells in mastocytosis 126. Thus, mast cells expressing variant 2 are 
demonstrably more active than those expressing variant 1.   
CXCR4 is a chemokine receptor for CXCL12 expressed by inflammatory cells 
including T cells, macrophages, and mast cells, and has been shown to play a role in mast 
cell recruitment 128-130. The CXCL12-CXCR4 pathway in mast cells has been implicated to 
play a role in several cancers, including UV induced skin cancer, glioblastoma, and prostate 
cancer 106,131,132. In addition, CXCR4 has been shown to be expressed by some prostate 
cancer cell lines including PC3 cells 133. In addition, one study in an obesity and myc-
induced mouse model found that the CXCR4-CXCL12 pathway was a driver in tumor 
migration and invasion, and blocking of CXCR4 sensitized the mice to chemotherapy 134.  
Finally, meta-analysis of human data has found CXCR4 is significantly more highly 
expression in prostate tumor tissue than benign prostate tissue, and is associated with a 
higher prostate cancer stage, but not Gleason score 135. This analysis also showed an 
association with lymph node involvement, bone metastasis, and poor prognosis.  
Interestingly, CXCR4 has also been highlighted in microarray studies as having higher 
expression in prostate cancer in African American men compared to Caucasian American 
men, potentially suggesting a role in the significant racial disparity found in prostate cancer 
93,105. Given our study, this may be an association worth further investigation.  
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TFE3 is a transcription factor previously reported to play a role in the functions of B 
and T cells, specifically in regulation of surface IgE and CD40L respectively 136. TFE3 has 
also been demonstrated to play a role in mast cell degranulation, mediator secretion, and 
histamine release in response to an allergic trigger, all of which are hallmarks of mast cell 
activation 136. In the context of cancer, TFE3 fusions have been identified in sarcomas 
(ASPS) and renal cell carcinoma, but not yet identified in prostatic adenocarcinoma 137. 
These data supports the hypothesis that mast cells, and their immediate 
microenvironments, are biologically different in tumor compared to benign tissues. As 
prostate cancer is an extremely heterogeneous tumor environment, this may serve as an 
explanation as to why the literature is contradictory as to the relationship between mast cells 
and prostate cancer progression. Our findings also have interesting implications for prostate 
cancer treatment, as the mast cell populations appear to be diverse, and therefore may not be 
predictable in response to direct targeting or prostate cancer therapies. Additional studies are 
necessary to elucidate the exact pathways mast cells may be contributing to tumor 
progression and metastasis. 
 
V. MAST CELLS IN ANIMAL MODELS OF PROSTATE CANCER 
 
5.1 Abstract 
Given our previous results suggesting a role for mast cells in PSA progression and 
metastasis, we next aimed to study whether mast cells may be playing a role in early invasion 
in prostate cancer. This is a question best asked in animal models, where prostate cancer 
development can be seen in different stages, as well as observed for direct cause and effect. 
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This was accomplished via two animal models; the rat PhIP model and the HiMyc-Wsh 
model. In the rat PhIP model, mast cells were quantified in the ventral prostates of rats that 
were treated with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and/or E. coli 
via transurethral infection and allowed to age another 32 weeks. In the HiMyc-Wsh mouse 
model, mast cell knock-out Wsh mice were crossed with the HiMyc mouse model to 
determine if the complete absence of mast cells would have an effect on the development of 
invasive carcinoma. In both models, mast cells were quantified via toluidine blue staining. In 
the PhIP model, mast cells were found to be increased in all rats treated with PhIP and/or E. 
coli even 32 weeks after treatment. In the HiMyc-Wsh model, the dorsal-lateral prostate was 
found to simultaneously have the most invasive carcinoma and the highest numbers of mast 
cells in wild-type and Wsh heterozygous mice. There was a decrease in invasive carcinoma 
in the mast cell knock-out Hi-Myc mice. Our findings support a role for mast cells in driving 
early invasion of prostate cancer. 
 
5.2 Introduction 
In our human studies of prostate cancer, evidence is mounting for a role for mast cells 
in predicting recurrence and metastasis. We next wanted to explore whether mast cells play a 
role in early invasion of prostate cancer, a question best addressed with animal models. 
Human radical prostatectomy specimens contain cancer that presumably developed many 
years prior to detection and treatment. We chose to pursue the question of early invasion via 
two rodent models, specifically the rat PhIP model and the HiMyc-Wsh mouse model. 
There have been a number of studies exploring potential roles of mast cells in prostate 
cancer in rodent models, including one study in TRAMP mice by Pittoni et al. In their study, 
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Pittoni et al explored the role of mast cell MMP9 in early prostate tumor progression in 
transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, arguing that lower grade 
prostate tumors would need mast cell-derived MMP9 for invasion, since well differentiated 
prostate tumor cells do not produce MMP9 114. The results did in fact suggest that mast cell 
MMP9 was necessary for early tumor invasion in mice. Immunohistochemistry (IHC) studies 
in human prostate cancer tissues showed a positive correlation between increased mast cell 
density, MMP9 production confined almost entirely to the tumor-infiltrating mast cells, and 
well differentiated tumors – supporting the observations observed in the TRAMP mouse 
studies 114.  Whether mast cell-derived MMP9 plays a role in driving early invasion of human 
prostate cancer is yet to be elucidated. One caveat of this model is that TRAMP mice are a 
model of neuroendocrine prostate cancer, while the majority of cases of prostate cancer in 
humans are adenocarcinoma. Consequently, we specifically wanted to study the role of mast 
cells in early invasion in models of adenocarcinoma. 
One of the pertinent rodent models of precancerous lesions of the prostate is the PhIP 
rat model, where dietary 2-amino-1-methyl-6-phenyl-imidazo[4,5-b]pyridine (PhIP) induces 
pre-invasive/carcinoma in situ lesions in the ventral prostates of Fischer344 rats 138. Previous 
studies have sought to understand the lobal specificity of the model, and Nakai et al found an 
increase in mutations in all lobes of the prostate upon dietary exposure of PhIP, thus 
suggesting that mutation does not alone explain the development of the precancerous lesions 
138. Nakai et al then quantified immune cells in this model, and found that macrophages and 
mast cells increased in number specifically in the ventral lobes upon PhIP exposure. These 
results suggested a potential role for inflammatory cells, including mast cells, in promoting 
precursor lesion development.  
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We aimed to study whether the increases in mast cells in the ventral lobes of the rats 
are a transient or a long term effect. To do this, tissues were used from a prior PhIP study 
performed by Sfanos et al. In this study, Fischer344 rats were treated with PhIP (200 ppm in 
the diet for 20 weeks), prostatic E. coli infection (prostatic inoculation at week 10), or both 
and monitored to an age of 52 weeks 139. This allowed us the opportunity to quantify mast 
cells in the ventral prostates of PhIP treated rats who had not received PhIP for 32 weeks, as 
well as rats with prostatic infection, elucidating whether the mast cell increase was simply in 
reaction to the presence of PhIP and/or inflammation, or if the increase was a long term 
effect. This was accomplished via toluidine blue staining and quantification of mast cells in 
the ventral lobes of the rats in each treatment group. While this study examined whether mast 
cells are simply reacting to the presence of mutagen in the microenvironment, this study does 
not actually elucidate a cause and effect relationship between mast cells and tumor invasion. 
Consequently, we then pursued a mast cell knock-out study in mice that are known to 
develop invasive prostate cancer as part of their aging process, in order to determine if the 
presence or absence of mast cells in the prostate has any effect on lesion growth and 
invasion. 
In pursuit of the question of whether the presence of mast cells can affect prostate 
cancer invasion, we conducted a mouse study where we crossed a well-known prostate 
cancer mouse model, the HiMyc mouse, with a mast cell knock-out mouse known as the Wsh 
mouse. The HiMyc mouse is on a BL6 background and over-expresses Myc in an androgen 
dependent manner in the prostate, developing PIN by 2 weeks and invasive carcinoma in the 
dorsal lateral prostate by 6 months 140. The Wsh mouse carries an inversion in the Corin 
promoter in a FVB background mouse, producing a lack of expression of C-kit, which results 
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in a mast cell knock-out model 141. Due to the mixed background nature of this cross, HiMyc-
Wsh mice were taken to the F2 generation, to produce littermates of all Myc and Kit 
genotypes in order to control as much as possible for mixed backgrounds as well as study the 
dosage effect of Wsh genotype on mast cell number and tumor invasion. In this mouse 
model, mast cells did not infiltrate into the tumor area. Consequently, this is a model 
studying the roles of extratumoral mast cells, specifically. 
  
5.3 Methods 
PhIP Rat model. Rats were treated with PhIP (200 ppm in the diet for 20 weeks), prostatic E. 
coli infection (prostatic inoculation at week 10), or both and monitored to an age of 52 
weeks. Prostates were dissected, formalin fixed, paraffin embedded, and ventral prostates 
stained with toluidine blue. Slides were scanned with an Aperio ScanScope® CS linear-array 
scanner (Leica Biosystems).  Mast cells were quantified in Aperio for a mast cell number per 
mm2 per ventral prostate.  
HiMyc-WSH mouse generation. HiMyc mice on an FVB background were crossed with Wsh 
mice on a BL6 background to the second generation to generate littermates of all genotypes, 
specifically HiMyc +/-Kit+/+, HiMyc +/-Kit+/-, HiMyc +/-Kit-/-, HiMyc -/-Kit+/-, and 
HiMyc -/-Kit-/-. All mice were second generation and littermates in order to control for 
mixed background as much as possible.  
Tissue processing. Prostates were dissected and fixed in 10% formalin for a minimum of 48 
hours. Tissues were then paraffin embedded and sectioned onto slides.  
Slide staining, annotation, and analysis. FFPE slides were H&E stained for annotation for 
PIN, cribiform PIN, and invasive area by prostate lobe. Adjacent slides were also stained 
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with toluidine blue (1% toluidine blue in 1% sodium chloride and 7% ethanol) for 
visualization and quantification of mast cells by lobe. Slides were scanned at 20X using the 
Aperio ScanScope (CS model, Aperio, Vista, CA) and annotated in Aperio Imagescope. 




Quantification of mast cells in the ventral lobes of PhIP-treated and/or E.coli infected 
rats. Mast cells were quantified in the ventral lobes of the prostates of study animals from all 
treatment groups (control, PhIP-treated, E. coli infected, and PhIP+E.coli) (Figure 5.1). PhIP 
treated mice were found to have significantly higher numbers of mast cells in their ventral 
lobes compared to control animals (P<0.005). E. coli infected and PhIP+E.coli mice had 
significantly higher numbers of mast cells compared to the PhIP-treated group (P<0.05). All 
PhIP-treated mice were 32 weeks out from treatment, showing that mast cell increases were a 
long term effect of PhIP treatment. 
Mast cell count by Wsh genotype. Quantification of mast cells showed the expected dosage 
effect of Wsh phenotype, where mast cell numbers in wild-type mice were significantly 
higher than heterozygous mice (Figure 5.2). Wsh homozygous mice contained no mast cells.  
Mast cell count by prostate lobe. Mast cell numbers were significantly higher in the dorsal-
lateral prostates of Wsh heterozygous mice compared to both the anterior (P=0.0208) and the 




Total invasive cancer area percent by genotype. 10 week old mice did not show a 
significant difference in PIN development by Wsh genotype (data not shown). However, 
aged (12 month old) Wsh WT mice had significantly higher total invasive cancer area 
compared to aged Wsh HT mice (P=0.009) (Figure 5.4).  
Invasive area percentage by lobe. As is expected with the HiMyc model, all HiMyc mice 
had significantly greater invasive area in the dorsal-lateral prostate lobes compared to the 
anterior lobe (P<0.0001) and the ventral lobe (P<0.0001) (Figure 5.5). 
Invasive area in dorsal-lateral prostate by Wsh genotype. Wild-type mice had 
significantly higher total invasive area in the dorsal-lateral prostate compared to 
heterozygous mice (P=0.01) (Figure 5.6).  
5.5 Discussion and Conclusions 
In our PhIP rat study, we determined whether mast cell numbers in the ventral 
prostate are increased in response to PhIP treatment in the long term, specifically 32 weeks 
post treatment. Our results showed that the increase in mast cells are indeed maintained in the 
long term in response to PhIP, as well as in response to E. coli infection of the prostate 
(Figure 5.1). The effects of treatment with both PhIP and E. coli infection did not appear to 
be additive (Figure 5.1). These results suggest that the mast cell increase was not just in 
response to the presence of PhIP or E. coli in the microenvironment, as ample time had 
passed to clear the PhIP and infection. This long term increase in mast cell number may be 






Figure 5.1. Quantification of mast cells in the ventral lobes of study rats. Rats treated 
with PhIP showed a significant increase in the number of mast cells even 32 weeks post 
treatment. There was also a significantly higher number of mast cells in rats treated with E. 
coli, and those treated with PhiP and E. coli. These results demonstrate that the increase of 
mast cells in the ventral lobe is a long term effect. * p < 0.005 versus control, ** p < 0.05 
versus PhIP. 
 
In our study in the Himyc-Wsh mice, we found that there was indeed higher invasive 
area in the dorsal-lateral prostates (DLP) of the mice as is expected with the HiMyc mouse 
model (Figure 5.5). Interestingly, we also found that the DLP had the highest number of mast 
cells of all the lobes in the prostates of the HiMyc mice in both Wsh wildtype and Wsh 
heterozygous mice (Figure 5.3). This suggests that the lobal specificity of invasive caner to 
the DLP of the HiMyc mouse model may be due to the presence of high numbers of mast 
cells in the dorsal-lateral lobes of the mice. In addition, total percent invasive area correlated 
with Wsh genotype, meaning that Wsh+/+ mice, which had no mast cells, had the lowest 
invasive area and the wildtype mice had the highest (Figure 5.4). This suggests a dosage 
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effect where higher numbers of mast cells resulted in higher percent invasive area, further 




Figure 5.2. Mast cell (MC) quantification. Mice with wild-type Wsh genotype (MC WT) 
had the highest mast cell count, followed by the heterozygous mice (MC HT), and Wsh 






Figure 5.3. Mast cell (MC) number by lobe. In Wsh heterozygous mice, the dorsal-lateral 
prostate had significantly higher numbers of mast cells compared to both anterior and ventral 
prostate, while anterior prostate had significantly higher mast cell counts compared to ventral 
prostate. Wsh wildtype mice (B) showed a similar trend. 
 
 
Figure 5.4 Total invasive area percent by genotype. Wild-type mice had significantly 





Figure 5.5. Total invasive area percent by prostate lobe. Invasive area percentage was 
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Figure 5.6. Total invasive area in DLP by genotype. Total invasive area was highest in the 




One caveat of the HiMyc-Wsh study was the mixed background of the model, as the 
HiMyc mouse is on a C57BL6/J background and the Wsh mouse is on a FVB background. 
Care was taken to keep the cross generations to second generation crosses, as well as produce 
each genotype as littermates, limiting the number of variables. In addition, there has been 
discussion over whether pure background mouse studies are indicative of human populations, 
so it may be appropriate to argue that the mixed background may be more illustrative of 
effects of mast cells in mixed populations of humans. 
 
VI. CONCLUSION AND PERSPECTIVES 
6.1 Mast cells and prostate cancer progression 
The relationship between mast cells and prostate cancer has intrigued scientists for 
some time. Since mast cells are present in the stroma of the healthy prostate and increase in 
the presence of prostate cancer, the possibility of interactions between mast cells and prostate 
cancer cells was probable. In addition, as mast cell densities are higher in lower Gleason 
score tumors than in higher Gleason scores, this relationship did not appear to simply be a 
linear relationship to the grade of the cancer. Consequently, a number of studies have been 
conducted to investigate the relationship between mast cells and progression in prostate 
cancer, with varied results. As was reviewed in Chapter II, Johannson et al found high 
intratumoral mast cell densities to be associated with longer cancer-specific survival 118. In 
our study detailed in Chapter II, our findings agreed with Johannson et al, with high 
intratumoral mast cell density being associated with a lower likelihood of PSA progression 
120. In addition, the results of our race disparities study detailed in Chapter III showed that 
low numbers of intratumoral mast cells were associated with higher risk of metastasis in both 
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African American and Caucasian American men. Finally, immunostaining of prostate cancer 
metastases in various rapid autopsy tissues showed no intratumoral mast cells, except in bone 
(Figure 3.1). As such, our results suggest that mast cells are excluded from highly aggressive 
prostate cancer with high metastatic potential, and that intratumoral mast cells may either 
play a protective role or are only allowed into the tumor microenvironment in well 
differentiated prostate cancer. Given these findings, our next step was to explore whether 
mast cells contributed to prostate cancer race disparities. 
As was reviewed in Chapter III, prostate cancer presents with a significant racial 
disparity, where African Americans are twice as likely to be diagnosed with prostate cancer 
compared to Caucasian Americans, and twice as likely to die from their disease. In addition, 
studies have shown prostate cancer to be more aggressive in African Americans, progressing 
earlier and faster than Caucasian Americans 87. Since our results in Chapter II suggest that 
mast cell density is associated with the potential of prostate cancer to progress or metastasize, 
we sought to determine if African Americans present at time of surgical intervention with 
lower intratumoral mast cell densities compared to Caucasian Americans. Our results, 
showed no significant difference in mast cell densities in higher Gleason score (Gleason ≥ 
4+3=7) tumors in AA men compared to CA men. AA men did however have lower densities 
of intratumoral mast cells in lower Gleason score tumors (Gleason ≤ 3+4=7), and we 
hypothesized that AA men with lower grade tumors may tend to do worse. We also stained 
and analyzed a high risk AA TMA to determine if mast cells have the same relationship with 
risk of recurrence in AA tissues as was observed in the PSA progression TMA in Chapter II. 
A similar trend was observed in our data where low intratumoral mast cells were associated 
with higher risk of PSA progression, however the association did not reach statistical 
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significance. We did, however, observe a significant relationship between low intratumoral 
mast cell density and higher rates of metastasis in both CA and AA men, leading us to 
consider whether the association observed in Chapter II was actually driven by metastasis. 
Given these data, we conclude that mast cells could be a contributing factor to prostate 
cancer aggressiveness given their relationship with metastasis and PSA progression in both 
AA and CA men.  
In addition to the inverse relationship between intratumoral mast cells and risk of 
PSA progression, we also observed a significant relationship between extratumoral mast cells 
and risk of PSA progression, where high densities of extratumoral mast cells were associated 
with a higher rate of PSA progression (Table 2.4, Figure 2.2). Given these results, we were 
interested to study whether mast cells play a direct role in tumor invasion. This was a 
question best studied in animal models, where cause and effect can be more easily observed. 
Previous studies had suggested a role for mast cell MMP9 in tumor invasion in better 
differentiated, or lower grade, tumors in in the TRAMP mouse model 114. In a study in the 
PhIP rat model, Nakai et al found that mast cells increased in the ventral lobes of treated rats, 
suggested a role for mast cells in the development of precursor lesions in the ventral lobes of 
the rats 138. We quantified mast cells in another PhIP rat study where the rats had been aged 
another 32 weeks post-PhIP treatment. Results showed that mast cells were significantly 
higher in the ventral lobes of rats treated with PhIP compared to control rats (Figure 5.1). 
These results led us to hypothesize that the increase in mast cells in the ventral lobes were 
not just a reactive inflammatory reaction, and was instead a long term increase that could be 
interacting with the epithelium in the absence of the PhIP. We also performed a study in mice 
where mast cell knock-out mice (Wsh mice) were crossed with HiMyc mice, which develop 
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invasive carcinomas in the dorsal-lateral, and to a lesser extent, the ventral and anterior lobes 
of the prostate. Our results showed that mast cell knock-out mice developed significantly 
lower invasive tumor area percentage (Figure 5.4). In addition, all mice developed the 
greatest invasive area percentage in their dorsal-lateral prostates (Figure 5.5), and the dorsal-
lateral prostate also had significantly higher numbers of mast cells than all other lobes 
(Figure 5.3). Similar to the Nakai study, these results suggest a role for mast cells in the lobal 
specificity of the rodent model, as well as suggest a role for mast cells in early tumor 
invasion.  
6.2 Mast cell phenotypes: implications of our findings 
Mast cells are known to separate into two classical subtypes, specifically MCtc (mast 
cells that make tryptase and chymase) and MCt (mast cells that make tryptase but not 
chymase). These subtypes do not appear to be final, however, and studies have shown mast 
cell subtype ratios to change in disease microenvironments 121. Mast cells are also known to 
be diverse in their protease profiles, and studies have shown differences in those profiles as 
mast cells develop from precursor cells in different tissue microenvironments 1,7. Given our 
results that mast cells have a differential relationship with risk of PSA progression depending 
on whether they are found inside or outside the tumor, we aimed to determine whether mast 
cells have different phenotypes based on their location in relationship with the tumor. This 
was accomplished by first analyzing mast cell subtypes in a race disparity TMA set (with the 
dual purpose of determining if AA tissues present with different mast cell subtype ratios 
compared to CA tissues). The results of these studies indicated that MCt cells may be 
proportionately more prevalent in the prostate tumor microenvironment than MCtc cells, 
86 
 
however there were no racial differences in the prevalence of tumor or benign tissue mast 
cell subtypes observed in our studies. 
Next, we used LCM and RNAseq to study mast cell expression profiles in greater 
detail. Using LCM to microdissect out toluidine blue staining cells, we were able to perform 
RNAseq to analyze the expression profiles of intratumoral versus benign tissue mast cells 
and their immediate microenvironments. The RNAseq results indicated significant 
differences between the collected tumor region and benign region mast cell mRNA. Mast cell 
related genes, including tryptase subunits, chymase, C-kit, and others, were strongly 
represented and of roughly equal expression in both tumor and benign, validating that mast 
cells were indeed enriched for in the samples (Table 4.3). Three genes of interest were 
chosen for validation and further exploration, specifically C-kit variant 1, CXCR4, and 
TFE3. RISH and qPCR protocols showed similar patterns as was seen in the RNAseq data, if 
not in the mast cells themselves, then in their immediate microenvironments and interacting 
cells. These results confirmed our hypothesis that there are significant differences between 
mast cells and their immediate microenvironments depending on whether they are found 
inside or outside the tumor. Our results also suggest that the explanation for our previous data 
where intratumoral and extratumoral mast cells had an opposite relationship with risk of PSA 
progression (Figures 2.2, 2.3) lies in the underlying biology of the mast cells themselves, as 
well as their cellular interactions. This has significant implications for the clinical application 
of our findings. 
While our results for the relationships between mast cells and risk of PSA 
progression, metastasis, and early invasion are significant, they are not robust enough to 
currently warrant a direct clinical application. Conversely, our results that biological 
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differences exist between intra- and extratumoral mast cells suggest that targeting mast cells 
for therapy in prostate cancer would be a very delicate and potentially dangerous prospect, as 
intratumoral mast cells appear to be potentially protective against metastasis (or at least 
excluded from the microenvironments of tumors with metastatic potential), while 
extratumoral mast cells may actually help drive tumor invasion. However, mast cells may 
prove a valuable tool as a prognostic indicator, especially in Gleason score 7 prostate cancer, 
where prognosis is less predictable and definitive treatment is unclear.  
In summary, mast cells are of interest in the context of cancer as they are diverse, 
dynamic, and could be either pro or anti-tumorigenic depending on the context. The 
experimental content of this thesis supports a role for mast cells in prostate cancer invasion, 
progression, and metastasis. As such, mast cells are an interesting potential prostate cancer 
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